

New Lupane Derived Compounds with Pro-Apoptotic Activity in Cancer Cells: Synthesis and Structure–Activity Relationships

Jan Šarek,[†] Jiří Klinot,[†] Petr Džubák,[‡] Eva Klinotová,[†] Věra Nosková,[†] Václav Křeček,[†] Gabriela Kořínková,[‡] Jean Oliver Thomson,[‡] Anna Janošťáková,[‡] Shudong Wang,^{||} Simon Parsons,[§] Peter M. Fischer,^{||} Nikolai Z. Zhelev,^{||} and Marián Hajdúch^{*,‡}

Department of Organic and Nuclear Chemistry, Charles University in Prague, Hlavova 8, 128 43 Prague 2, Czech Republic, Laboratory of Experimental Medicine, Department of Pediatrics, Faculty of Medicine, Palacký University and Faculty Hospital in Olomouc, Puskinova 6, 775 20 Olomouc, Czech Republic, Department of Chemistry, The University of Edinburgh, Joseph Black Chemistry Building, The King's Buildings, West Mains Road, Edinburgh, EH9 3JJ, United Kingdom, and Cyclacel Limited, James Lindsay Place, Dundee DD1 5JJ, United Kingdom

Received February 25, 2002


Cellular screening of various synthetic triterpenoid compounds formally derived from lupane has identified a number of analogues as potential anticancer drug candidates. Here we describe the synthesis and structure–activity relationships of betulin and betulinic acid derivatives containing an E-ring modified with different oxygen functions. Thus compounds containing the lup-18-en-21-one, lup-18-ene-21,22-dione, 18,19-secolupane, and the highly oxygenated 18,19-secolupane systems, as well as des-E-lupane derivatives, were prepared from the readily available natural pentacyclic triterpene betulin using oxidative procedures. These compounds were named betulinines. We demonstrate that only selected compounds, particularly those containing a lupane E-ring-derived unsaturated ketone or diketone function, possessed *in vitro* cytotoxic activity against tumor cell lines, suggesting a structure–activity relationship.

Introduction

The antitumor properties of lupane (**1**, Chart 1) derived triterpenoid compounds were first discovered over 20 years ago when extracts from the stem bark of various plants was tested for cytostatic activity using different *in vivo* cancer model systems.^{1–5} This led to the isolation of the pentacyclic triterpene betulinic acid (BA; **2b**), the best-known representative of the lupane-derived compounds with antiproliferative properties.⁶ Early data about both the *in vitro* and *in vivo* antitumor activity of BA remain controversial, however. For example, original observations² regarding the efficacy of BA in the Walker 256 murine carcinosarcoma model could not be reproduced using a similar system.³ Antitumor activity of BA against P388D1 murine leukaemia tumors was also suggested.⁴

More recent studies have shown selective cytotoxicity of BA against human melanoblastoma cells.⁷ Cell cycle analysis of melanoma cells exposed to BA revealed a G₀/G₁ block after 32 h exposure, and induction of apoptosis was observed after 56–72 h. In addition to this antimelanoma specificity, other studies demonstrated an antitumor effect against neuroectodermal tumors. Furthermore, there is also evidence that BA induces apoptosis via the activation of caspases and that the cytotoxic activity is independent of cellular p53 gene status and CD95 activation.⁸ Interestingly, apoptosis is mediated via direct effects on mitochondria, since induction of mitochondrial permeability transition by BA

Chart 1



alone was sufficient to trigger a full apoptosis progression.⁹ It is also worth mentioning that BA itself, as well as some derivatives, have been described as potent anti-HIV agents.^{10,11}

The screening of various lupane-derived triterpenoid compounds synthesized in our laboratories has now identified a number of novel potentially active anticancer drugs. In this report, we describe the synthesis and structure–activity relationships of derivatives of BA, in which the E-ring is modified with different oxygen functions, e.g., 18-lupen-21-one, 18-lup-21,22-dione, 18,19-secolupane, the highly oxygenated 18,19-secolupane, and des-E-lupane. We have named these compounds betulinines. It is known¹² from the literature that the cytotoxic activity of isoprenoid carboxylic acid derivatives is often related to the presence of a free carboxyl group in the molecule. The activity of the corresponding alkyl esters is often much less.¹² This fact is often explained by the comparatively poor hydrolytic lability of alkyl esters under physiological conditions. Pivaloyloxymethyl (Pom) and acetoxymethyl (Acm) esters, on the other hand, which are based on dihydroxymethane, are hydrolyzed readily by various non-specific enzymes.¹³ These esters can be used as suitable

* To whom correspondence should be addressed. Telephone: +420-58-5854421. Fax: +420-58-58525227. E-mail: hajduchm@atlas.cz.


[†] Charles University.

[‡] Palacký University and Faculty Hospital in Olomouc.

[§] The University of Edinburgh.

^{||} Cyclacel Limited.

Scheme 1



prodrug groups for carboxylic acids. Because of their lipophilic character, they are membrane permeable and their purification is much easier than that of free carboxylic acids.

In this study, 3 β -acetoxyupane derivatives with oxidative modifications of the E-ring and variously bearing acetoxyethyl, carboxyl, methoxycarbonyl, (pivaloyloxy)methoxycarbonyl, and acetoxyethoxycarbonyl groups at C17 were prepared and tested. The cytotoxic activity of this series of derivatives was assessed comparatively using human tumor cell lines.

Chemistry


The starting material for the preparation of the compounds described here was 21-oxolup-18-ene-3 β ,28-diyl diacetate **3a** (Scheme 1). This unsaturated ketone is readily obtained from the natural triterpene betulin **2a** through successive acetylation, acid-catalyzed isomerization of the 20(29)-double bond,¹⁴ and allylic oxidation of the resulting 18,19-unsaturated product.¹⁵ Selective saponification of the 28-acetate ester then furnished

hydroxy ketone **3b**,¹⁶ whose carbinol function was oxidized to the carboxylic acid **3c** in high yield with RuO₄. Methyl ester **3d**, which has been described previously,¹⁷ was also characterized. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU)-mediated reactions of keto acid **3c** with chloromethyl pivalate¹³ or with bromomethyl acetate in dichloromethane-acetonitrile mixtures afforded the Pom and Acm esters **3e** and **3f**, respectively. Selenium dioxide oxidation of 21-ketones **3a** and **3d-f** in dioxane/acetic acid cleanly yielded the corresponding 21,22-diketones **4a-d**. Using ¹H NMR analysis it was found that α -diketones **4b-d** reacted very easily with simple alcohols, producing complicated mixtures of hemiketals and ketals; this finding ruled out the use of alcohols as recrystallization solvents.

The 21-ketones **3a** and **3d-f**, as well as 21,22-diketone **4a**, were used for the synthesis of the 18,19-secolupane derivatives **5** and **6**. For fission of the 18,19-double bond in the 21-oxo and 21,22-dioxo derivatives, ruthenium(IV) oxide was used in a catalytic mode (15 mol %). Ruthenium(VIII) oxide was generated in situ from ruthenium(IV) oxide with sodium periodate in a two-phase system of ethyl acetate and water. A similar approach was used by Russian authors¹⁸ for the fission of the double bond in unsubstituted 18-lupenes. Regioselectivity and reaction yields were excellent with this system, although reaction times were often long (1–6 days). The resulting triketones **5a-d** and tetraketone **6** are stable crystalline compounds, existing, according to ¹³C NMR, in exclusively the nonhydrated oxo-form. However, attempts to cleave the diketone functions in these compounds with lead tetraacetate or sodium periodate did not lead to nor-derivatives of tetranoracids of type **7**. Instead, the latter compounds were obtained through Baeyer–Villiger rearrangement with the aid of peroxyacetic acid and they were characterized as the free acids **7a** and **7d**, or in the form of methyl esters **7b** and **7e-g**. Tetranoracid **7a** was then lactonized easily to the previously known spiro lactone **14**.¹⁹ Through retro-aldol reaction of **7a**, followed by methylation and acetylation, pentanorlupane derivative **7c** was obtained. This compound had previously been prepared by a different approach.¹⁹

Tetraketone **6** was obtained by ruthenium-catalyzed oxidative degradation of diketone **4a**. Yields of **6** were improved by addition of acetonitrile to the reaction mixture²⁰ and an increase in the catalytic amount of ruthenium(IV) oxide to 17 mol %. Carboxylic acid **8a** was prepared by cleavage of tetraketone **6** with peroxyacetic acid as reported.²¹ Compound **8a** could also be obtained by oxidative fission of the diene **10**, which in turn was obtained by a single-step reaction²² from lup-18-ene-3 β ,28-diyl diacetate. However, despite the shorter synthetic route from betulin, the latter method is not as suitable for larger scale preparations of key compound **8a** as the former route via tetraketone **6**, or indeed an alternative route via anhydride **9a** we have reported on previously.²³ Methyl ester **8b** was obtained in the usual manner, whereas attempts to prepare Pom-ester **8c** were not successful. Similarly, application of the DBU-mediated alkylation method referred to above did not permit preparation of Acm-ester **8d** and only decomposition products were obtained. Nevertheless, **8d**

Scheme 2



could be prepared by alkylation of the silver carboxylate salt of acid **8a** in dimethylformamide.

The relative stability of keto acid **8a**, which on theoretical grounds one would expect to decarboxylate spontaneously, is probably due to steric congestion induced by the 17β -acetoxymethyl group, thus hindering formation of the requisite six-membered ring intermediates necessary in the cyclic mechanism of decarboxylation between the 18-oxo and 17α -carboxylate groups. It is known,¹⁸ however, that if the carboxylic function is in position 17β , the corresponding 18-keto derivatives decarboxylate spontaneously.

β -Keto acid **8a** was used for the preparation of other highly degraded lupane and des-E lupane derivatives (Scheme 2). Heating of β -keto acid **8a** in boiling diglyme led to formation of a complicated product mixture through thermal decomposition. Two of the three main components could be identified, the known heptanorketoacetate **11b**²⁴ and methylene ketone **12**, an unstable compound that was isolated by lyophilization from benzene; the third compound was very unstable and could not be identified.

Very unusual is the reaction of β -keto acid **8a** with potassium hydroxide. If this reaction is performed in the presence of ethanol, the ether **13a** appears in the product mixture along with the normal product of the retroaldol reaction, which then undergoes decarboxylation to the heptanorketone **11a**. One of the possible

explanations of the origin of the ethoxy derivative **13a** is Michael addition of ethanol to methylene ketone **12** under the basic conditions applied. If dioxane instead of ethanol is used as the solvent, high yields of pure heptanorketone **11a** could be isolated.

Oxidative fission of the $17(28)\text{-double}$ bond of methylene ketone **12** produced heptanor- $17,18\text{-seco}$ diacid **15a**.²⁵ This acid can also be prepared by fission of the double bond in hydroxy ketone **3b** or acid **3c**. Dimethyl ester **15b**²⁵ was prepared from the diacid **15a**. The new diPom-ester **15c** was also prepared, but it was impossible to obtain it in crystalline form. The structures of all the compounds were confirmed by spectral analysis. Furthermore, the structure and absolute configuration of key compound **8a** was confirmed through a single-crystal X-ray structure (see Figure 1; refer also to the Supporting Information).




Figure 1. ORTEP-style plot of one of the two crystallographically independent molecules of **8a** in the single-crystal structure. Ellipsoids are drawn at the 30% level.




Figure 2. Screening of cytotoxic activity of synthesized lupane derivatives on the chemosensitive CEM T-lymphoblastic leukaemia cell line.

Synthesis of the compound **8a**, described here, was successfully scaled-up to 100 g, with the same yields and purity. Betulin, the starting material for the six-step synthesis of **8a**, is a waste product from the industrial production of paper from birch wood. Estimated production of betulin is thousands of tons per annum. Therefore, a large-scale availability of the compound **8a** is both cost-effective and ecological. Ecology of production is further supported by the fact that the six-step process was optimized with no industrial waste.

Results and Discussion

Since betulinines are complicated natural compounds with lipophilic and rigid carbon skeleton, they are soluble in chlorinated solvents (e.g. chloroform) or ethers (e.g. THF, dioxane) but poorly soluble in water and water-based solvents. However, some of these compounds, particularly those with a free carboxylic group, can be dissolved in a water-ethanol system using pharmaceutically acceptable vehicles.

To evaluate the anticancer potency of our betulinines, their cytotoxic activity against the drug-sensitive CEM cell line was initially examined in the screening assay (Figure 2). It was followed by expanded activity analysis against typical representatives of epithelial, neuroectodermal, and mesodermal tumor cell lines (refer to the Supporting Information). Potent compounds with TCS₅₀ (concentration with 50% tumor cell survival) in the low micromolar concentration range were further tested on a panel of cell lines of different histogenetic

and species origin (Table 1). It can be seen that nonmalignant cells, e.g. NIH3T3 fibroblasts and normal human lymphocytes, tolerated substantially higher doses of betulinines than the tumor cells, thus demonstrating a preferential cytotoxicity for malignant cells and a favorable therapeutic index.

We show here that only selected derivatives of BA (**2b**) were active against CEM cells under in vitro conditions, suggesting a structure-activity relationship. From the results of the in vitro MTT tests it follows that the cytotoxic activity of the betulinines is often due to the presence in the triterpenic molecule of a β -dicarbonyl group, e.g. as in compounds **4b**, **4d**, **5d**, **7a**, and **8a**, or of an α -unsaturated ketone, e.g. in compounds **3a** and **16**.

The cell cycle and apoptosis analyses clearly demonstrate that the most active BA (**2b**) derivatives (**4a**, **8a**, **16**) induce apoptosis in CEM cells, which was demonstrated by both the flow-cytometry and scanning electron microscopy techniques (Figures 4 and 5). However, the compounds differed mostly in time dependency of apoptosis induction. The most active was compound **8a**, where the first sub-G1 cells appeared as soon as 3 h after the treatment, although no specific cell cycle alterations were observed. On the other hand, in the CEM cells treated with compounds **4b** and **16** the first signs of apoptosis were between 24 and 48 h after treatment. Interestingly, compound **16** also induced an accumulation of cells in the G2/M and S regions. We hypothesize that the increase in the S phase fraction could be due to the induction of apoptosis at the G2/M

Table 1. Cytotoxicity of Selected Lupane Derivatives (**2b**, **4b**, **8a**, **16**) in a Panel of Cell Lines of Different Histogenetic Origin and Having Various Phenotype Alterations (mean \pm SD)

| cell line | description ^a | cytotoxicity (TCS ₅₀ , μ M) | | | |
|--------------|---|--|------------------|-----------------|------------------|
| | | 2b | 4b | 8a | 16 |
| B16 | mouse melanoma | 30.5 \pm 3.72 | 35.4 \pm 3.47 | 0.43 \pm 0.25 | 9.32 \pm 1.05 |
| B16F | mouse melanoma, metastatic | 4.6 \pm 0.38 | 67.9 \pm 5.14 | 4.66 \pm 0.52 | 12.4 \pm 0.92 |
| SW620 | human colon cancer, metastasis | >250 | 5.89 \pm 0.47 | 1.22 \pm 0.11 | 5.86 \pm 0.61 |
| U87MG | human glioblastoma | >228 \pm 24.7 | 23.8 \pm 2.43 | 1.85 \pm 0.53 | 98.3 \pm 3.95 |
| HepG2 | human hepatocellular carcinoma | 3.61 \pm 0.28 | 5.14 \pm 0.55 | 1.67 \pm 0.09 | 7.12 \pm 0.82 |
| A549 | human lung adenocarcinoma | 79.3 \pm 6.3 | 6.7 \pm 0.73 | 2.8 \pm 0.34 | 43.27 \pm 3.78 |
| MCF-7 | human breast cancer, estrogen dependent, p53 ^{+/+} , RB ^{+/+} | 194 \pm 15.8 | 12.9 \pm 1.17 | 2.3 \pm 0.20 | 4.3 \pm 0.52 |
| U2OS | human osteosarcoma, p53 ^{+/+} , RB ^{+/-} | >250 | 4.28 \pm 0.44 | 1.53 \pm 0.15 | 3.94 \pm 0.43 |
| Saos2 | human rhabdomyosarcoma, p53 ^{-/-} , RB ^{-/-} | >250 | 7.9 \pm 0.83 | 1.78 \pm 0.22 | 4.8 \pm 0.51 |
| BT549 | human breast cancer, p53 ^{mut/mut} | >250 | 15.3 \pm 1.31 | 2.03 \pm 0.17 | 6.28 \pm 0.49 |
| MDA-MB-2 38 | human breast cancer, estrogen independent, p53 ^{mut/mut} | 195 \pm 15.3 | 3.28 \pm 0.39 | 1.35 \pm 0.1 | 2.37 \pm 0.18 |
| LNCaP | human prostate cancer, androgen dependent | 244 \pm 11.7 | 3.26 \pm 0.29 | 1.12 \pm 0.15 | 3.55 \pm 0.36 |
| DU145 | human prostate cancer, androgen independent, RB ^{-/-} | 241 \pm 22.9 | 1.98 \pm 0.25 | 0.84 \pm 0.11 | 2.75 \pm 0.30 |
| HT-29 | human colon cancer | >250 | 5.23 \pm 0.44 | 3.57 \pm 0.24 | 12.31 \pm 1.68 |
| OVCAR-3 | human ovarian cancer | 164 \pm 15.8 | 4.65 \pm 0.38 | 0.9 \pm 0.10 | 2.59 \pm 0.19 |
| Caco-2 | human colon cancer | 19.6 \pm 2.04 | 8.13 \pm 0.79 | 2.97 \pm 0.28 | 7.72 \pm 0.86 |
| MEL-3 | human melanoma | 2.65 \pm 0.35 | 5.86 \pm 0.63 | 1.28 \pm 0.21 | 3.68 \pm 0.37 |
| lymphocytes | human normal lymphocytes | >250 | 85.3 \pm 9.15 | 12.5 \pm 1.13 | 24.9 \pm 2.11 |
| NIH3T3 | mouse immortalized fibroblasts | >250 | 96.8 \pm 10.37 | 7.21 \pm 0.83 | 15.7 \pm 1.84 |
| K562 | human promyelocytic leukemia | 53.9 \pm 5.79 | 1.85 \pm 0.22 | 0.19 \pm 0.20 | 15.12 \pm 1.93 |
| K562-CdA | human promyelocytic leukemia, cladribin resistant | >250 | 5.17 \pm 0.62 | 0.28 \pm 0.03 | 2.13 \pm 0.24 |
| K562-GEM | human promyelocytic leukemia, gemcitabin resistant | 101 \pm 9.77 | 5.04 \pm 0.61 | 0.94 \pm 0.10 | 2.36 \pm 0.25 |
| K562-ARA-C | human promyelocytic leukemia, cytarabin resistant | >250 | 6.42 \pm 0.49 | 0.63 \pm 0.07 | 1.59 \pm 0.18 |
| K562-FLU D | human promyelocytic leukemia, fludarabin resistant | >250 | 4.85 \pm 0.54 | 0.35 \pm 0.41 | 1.27 \pm 0.13 |
| CEM | human T-lymphoblastic leukemia | >250 | 4.4 \pm 0.23 | 1.0 \pm 0.14 | 4.0 \pm 0.32 |
| CEM-DNR 1/C2 | human T-lymphoblastic leukemia, daunorubicin resistant | >250 | 10.3 \pm 0.11 | 0.61 \pm 0.58 | 1.58 \pm 0.17 |
| CEM-DNR bulk | human T-lymphoblastic leukemia, daunorubicin resistant | >250 | 5.18 \pm 0.49 | 1.05 \pm 0.09 | 3.26 \pm 0.41 |
| CEM-VCR 1/F3 | human T-lymphoblastic leukemia, vincristin resistant | 19.1 \pm 2.04 | 38.3 \pm 4.15 | 3.27 \pm 0.39 | 5.94 \pm 0.47 |
| CEM-VCR 3/D5 | human T-lymphoblastic leukemia, vincristin resistant | 24.1 \pm 2.63 | 12.5 \pm 1.08 | 2.93 \pm 0.33 | 7.82 \pm 0.86 |
| CEM-VCR bulk | human T-lymphoblastic leukemia, vincristin resistant | 68.5 \pm 7.19 | 28.2 \pm 2.95 | 2.51 \pm 3.07 | 6.95 \pm 0.58 |

^a The majority of genetic alterations referred to here are described at <http://www.atcc.org/>.

transition and the appearance of the sub-G2 cells, i.e., the population analogous to sub-G1 cells but having a tetraploid DNA content. Although this explanation is further supported by the persistence of the S phase/sub-G2 cells for as long as 18 h after the disappearance of the G0/1 populations among the paclitaxel-treated CEM lymphoblasts, further studies should precisely specify the site and mechanism of action of these molecules.

Although BA has been reported to be preferentially effective against neuroectodermal tumors,^{7–9} its derivatives described in this study have lost their specificity and demonstrated a broad anticancer potency (Table 1). Thus, the lack of significant activity correlation of BA with active betulinines of this study (Figure 3) is consistent with this observation. On the other hand, the effectiveness of most of the active betulinines described in Table 1 is significantly correlated (Figure 3), suggesting a common mechanism of action, although the different kinetics of apoptosis induction of **8a** versus **4b/16** compounds would suggest independent targets (Figure 4). However, we propose that this difference in timing of apoptosis is rather due to the dissimilar physical and/or pharmaceutical properties of these molecules, e.g., solubility, intracellular penetration, stability, metabolic activation.

Notably, a similar effectiveness of the betulinines was also found on cell lines bearing various mutations or deletions in the cell-cycle-associated proteins (Table 1). This fact indicates that betulinines such as compound **8a** should be equally effective on tumors with various alterations of tumor suppressor genes, such as p53 and the retinoblastoma protein pRb. We also note that the cytotoxic activity of the betulinines is independent of

the hormonal status of the cancer cells, and therefore, compounds should be equally effective in the treatment of hormone-dependent and -independent cancers (Table 1). Finally, the betulinines were effective on both the drug-resistant cell lines and the drug-sensitive counterparts. These data demonstrate that the classical mechanisms of multidrug resistance will apparently not apply to this novel generation of compounds, and thus, they could provide significant therapeutic benefit to chemotherapy-resistant cancer patients.

Experimental Section

General. Melting points were determined using a Kofler block and are uncorrected. Optical rotations were measured using CHCl₃ solutions (unless otherwise stated) on an Autopol III (Rudolph Research, Flanders, NJ) polarimeter, with an accuracy of $\pm 2^\circ$. NMR spectra were recorded on a Varian UNITY INOVA 400 instrument (¹H NMR spectra at 399.95 MHz) using CDCl₃ solutions (unless otherwise stated), with SiMe₄ as an internal standard. EIMS spectra were recorded on an INCOS 50 (Finigan MAT) spectrometer at 70 eV and an ion source temperature of 150 °C. The samples were introduced from a direct exposure probe at a heating rate of 10 mA/s. Relative abundances stated are related to the most abundant ion in the region of $m/z > 50$. TLC was carried out using silica gel 60 F₂₅₄, and detection was by spraying with 10% aqueous H₂SO₄ and heating to 150–200 °C. Column chromatography was performed using silica gel 60 (Merck 7734). For preparative HPLC, a normal phase silica gel column (250 \times 25 mm, Biospher 7 μ m), pump Gilson, and differential-refractometer detector (Laboratorní přístroje, Praha, Czech Republic) were used.

Acetate esters were prepared by overnight esterification at room temperature with a 1:1 mixture of pyridine and Ac₂O. Workup refers to pouring of the reaction mixture into H₂O; extraction of the product with Et₂O; and washing of the organic




Figure 3. Spearman correlation analysis of in vitro cytotoxic activity of betulinic acid (**2b**) and the most effective derivatives **16**, **4b**, and **8a** (r , correlation coefficient; p , statistical significance).

layer successively with H₂O, dilute aqueous HCl, H₂O, saturated aqueous NaHCO₃, and again H₂O, followed by drying over MgSO₄, filtration, and evaporation of the filtrate under the reduced pressure. Analytical samples were dried over P₂O₅ under diminished pressure. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), bromomethyl acetate (AcM-Br), chloromethyl pivalate (Pom-Cl), silver carbonate, and ruthenium(IV) oxide hydrate were purchased from Aldrich. Ketone diacetate **3a**,¹⁵ diene **10**,²² and aldehyde **16**²⁶ were prepared according to literature procedures. Betulinic acid **2b** was obtained by extraction of the bark of plane trees (*Platanus x hybrida*) with MeOH and several crystallizations from the same solvent.

28-Hydroxy-21-oxolup-18-en-3 β -yl Acetate (3b). A slightly modified literature procedure¹⁶ was used: a solution of usaturated ketone diacetate **3a** (10 g, 18.5 mmol) and KOH (1.25 g, 22.5 mmol) in PhMe/EtOH (1:1, 0.6 L) was stirred vigorously for 6 h, when TLC (hexane/EtOAc 1:1) indicated complete reaction. After workup a white crystalline residue was obtained, which was recrystallized from EtOAc to afford **3b** (8.2 g, 90%, mp 310–313 °C dec): $[\alpha]_D -67^\circ$ (c 0.48); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.93 (s, 3H, CH₃), 0.95 (s, 3H, CH₃), 1.13 (s, 3H, CH₃), 1.19 (d, $J = 6.9$ Hz, 3H, CH₃), 1.21 (d, $J = 6.9$ Hz, 3H, CH₃), 1.92 (d, $J = 18.6$ Hz, 1H, C²²H^F), 2.05 (s, 3H, OCOCH₃), 2.44 (d, $J = 18.6$ Hz, C²²H^F), 2.78 (dd, $J = 12.5$ Hz, $J = 3.4$ Hz, 1H, C¹³H^F), 3.19 (sept., $J = 6.9$ Hz, 1H, C²⁰H), 3.67 (d, $J = 10.7$ Hz, 1H, C²⁸H^F), 3.72 (d, $J = 10.7$

Hz, 1H, C²⁸H^F), 4.49 (dd, $J = 11.0$ Hz, $J = 5.5$ Hz, 1H, C³H^F). Ref.¹⁶ mp 292–294 °C, $[\alpha]_D -69^\circ$ (c 0.57).

3 β -Acetoxy-21-oxolup-18-en-28-oic Acid (3c). A suspension of hydroxy ketone **3b** (1.59 g, 3.2 mmol) in EtOAc (135 mL) was added to a mixture of Ru(IV)O₂·H₂O (40 mg, 0.3 mmol), NaIO₄ (4 g, 19 mmol), H₂O (120 mL), and CF₃COOH (2 mL). The biphasic mixture was stirred vigorously for 6 h. EtOH was then added and the mixture was filtered. The organic phase was separated and filtered through a short column of SiO₂. The column was washed with EtOAc and the filtrate was evaporated under reduced pressure. The residue was washed with Et₂O and was crystallized from butanone to afford **3c** (1.06 g, 66%, mp 222–239 °C): $[\alpha]_D -40^\circ$ (c 0.42 dioxane); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.92 (s, 3H, CH₃), 0.94 (s, 3H, CH₃), 1.06 (s, 3H, CH₃), 1.21 (d, 3H ($J = 7.0$ Hz, CH₃), 1.22 (d, $J = 7.0$ Hz, CH₃, 3H), 2.03 (s, 3H, OCOCH₃), 2.20 (br. d, $J = 18.6$ Hz, 1H, C²²H^F), 2.47 (m, 1H, C¹⁶H^F), 2.59 (d, $J = 18.6$ Hz, 1H, C²²H^F), 2.76 (dd, $J = 12.7$ Hz, $J = 3.2$ Hz, 1H, C¹³H^F), 3.21 (sept., $J = 7.0$ Hz, 1H, C²⁰H), 4.49 (dd, $J = 11.0$ Hz, $J = 5.5$ Hz, 1H, C³H^F); EIMS m/z 512 (M⁺, 13), 468 (16), 452 (8), 437 (4), 426 (1), 409 (28), 393 (7), 365 (8), 317 (3), 264 (8), 249 (78), 229 (11), 218 (11), 205 (100), 189 (94). Anal. (C₃₂H₄₈O₅) C, H.

Methyl 3 β -Acetoxy-21-oxolup-18-en-28-oate (3d). This compound was obtained from keto acid **3c** (250 mg, 0.49 mmol) by esterification with diazomethane. Crystallization from




Figure 4. Apoptosis and cell cycle analysis of CEM cells untreated (control) or treated with betulinic acid (**2b**) and the most effective derivatives **16**, **4b**, and **8a** ($10 \mu\text{M}$). Paclitaxel-treated cells ($1 \mu\text{M}$) were used as a positive control for both apoptosis and specific cell cycle block on G2/M transition (typical example of several independent experiments).

MeOH afforded **3d** (213 mg, 83%, mp 220–222 °C): $[\alpha]_{\text{D}} -33^{\circ}$ (c 0.39). $^1\text{H NMR}$ δ 0.84 (s, 3H, CH_3), 0.85 (s, 3H, CH_3), 0.91 (s, 3H, CH_3), 0.93 (s, 3H, CH_3), 1.03 (s, 3H, CH_3), 1.21 (d, $J = 7.0$ Hz, 6H), 2.05 (s, 3H, OCOCH_3), 2.13 (d, $J = 18.7$ Hz, 1H,

C^{22}H), 2.46 (d, $J = 18.7$ Hz, 1H, C^{22}H), 2.48 (ddd, $J = 13.5$ Hz, $J' = 3.9$ Hz, $J'' = 2.7$ Hz, 1H, C^{16}H), 2.64 (dd, $J = 12.7$ Hz, $J' = 3.2$ Hz, 1H, C^{13}H), 3.20 (sept., $J = 7.0$ Hz, 1H, C^{20}H), 3.70 (s, 3H, OCH_3), 4.49 (dd, $J = 11.0$ Hz, $J' = 5.3$ Hz, 1H,




Figure 5. Scanning electron microscopy study of apoptosis induction in CEM cells untreated (control) or treated with betulinic acid (**2b**) and the most effective derivatives **16**, **4b**, and **8a** ($10 \mu\text{M}$). (A) Typical morphology of cells after 24-hour treatment. Arrows indicate morphological markers of apoptosis: cytoplasm membrane blabbing, cellular fragmentation, and formation of apoptotic bodies (magnification $3600\times$). (B) Dynamics of the process is expressed as percentages of apoptotic cells ($x \pm \text{SD}$) at different time points.

$\text{C}^3\text{H}^{\text{F}}$); EIMS m/z 526 (M^+ , 4), 483 (1), 466 (2), 441 (1), 435 (1), 423 (5), 369 (1), 331 (1), 315 (1), 287 (1), 276 (3), 263 (56), 203 (13), 189 (22). Ref.¹⁷ mp $238\text{--}241^\circ\text{C}$ ($\text{CH}_2\text{Cl}_2/\text{MeOH}$), $[\alpha]_{\text{D}} -29^\circ$ (CHCl_3). Anal. ($\text{C}_{33}\text{H}_{50}\text{O}_5$), C, H.

(Pivaloyloxy)methyl 3 β -Acetoxy-21-oxolup-18-en-28-oate (3e). DBU ($165 \mu\text{L}$, 1.1 mmol) and Pom-Cl ($160 \mu\text{L}$; 1.1 mmol) were added to a solution of the keto acid **3c** (500 mg , 0.98 mmol) in CH_2Cl_2 (2.5 mL) and MeCN (1 mL). The mixture was stirred at room temperature for 3 h. It was then diluted with ice-cold H_2O and extracted with CHCl_3 . The extract was washed with cold brine, dried, and evaporated. The residual viscous pale yellow oil (750 mg) was chromatographed on SiO_2 (PhMe). Crystallization from MeOH afforded the Pom-ester **3e** as colorless needles (453 mg , 72% , mp $179\text{--}180^\circ\text{C}$): $[\alpha]_{\text{D}} -18^\circ$ (c 0.36); $^1\text{H NMR}$ δ 0.85 (s, 3H, CH_3), 0.86 (s, 3H, CH_3), 0.91 (s, 3H, CH_3), 0.93 (s, 3H, CH_3), 1.06 (s, 3H, CH_3), 1.19 (d, $J = 7.0 \text{ Hz}$, 3H, CH_3), 1.21 (d, $J = 7.0 \text{ Hz}$, 3H, CH_3), 1.20 (s, 9H, $\text{C}(\text{CH}_3)_3$), 2.05 (s, 3H, OCOCH_3), 2.14 (dd, $J = 18.7 \text{ Hz}$, $J = 0.8 \text{ Hz}$, 1H, $\text{C}^{22}\text{H}^{\text{F}}$), 2.46 (d, $J = 18.7 \text{ Hz}$, 1H, $\text{C}^{22}\text{H}^{\text{F}}$), 2.48 (ddd, $J = 13.4 \text{ Hz}$, $J = 4.1 \text{ Hz}$, $J' = 2.6 \text{ Hz}$, 1H, $\text{C}^{16}\text{H}^{\text{F}}$), 2.67 (dd, $J = 12.7 \text{ Hz}$, $J = 3.7 \text{ Hz}$, 1H, $\text{C}^{13}\text{H}^{\text{F}}$), 3.19 (sept., $J = 7.0 \text{ Hz}$, 1H, C^{20}H), 4.49 (dd, $J = 11.0 \text{ Hz}$, $J = 5.4 \text{ Hz}$, 1H, $\text{C}^3\text{H}^{\text{F}}$), 5.66 (d, $J = 5.5 \text{ Hz}$, 1H, OCH_2O), 5.84 (d, $J = 5.5 \text{ Hz}$, 1H, OCH_2O). EIMS m/z 626 (M^+ , 6), 611 (1), 596 (28), 583 (4), 566

(4), 536 (5), 512 (4), 467 (22), 452 (12), 437 (2), 423 (2), 409 (20), 391 (4), 363 (17), 333 (76), 249 (48), 216 (7), 203 (100), 189 (38). Anal. ($\text{C}_{38}\text{H}_{58}\text{O}_7$) C, H.

Acetoxymethyl 3 β -Acetoxy-21-oxolup-18-en-28-oate (3f). Keto acid **3c** (500 mg , 0.98 mmol) was treated with AcM-Br and DBU in CH_2Cl_2 (2.5 mL) and MeCN (1 mL) in the same manner as in the preparation of Pom-ester **3e**. Crystallization from butanone produced the AcM-ester **1f** as colorless needles (433 mg , 76% , mp $233\text{--}235^\circ\text{C}$): $[\alpha]_{\text{D}} -26^\circ$ (c 0.4); $^1\text{H NMR}$ δ 0.84 (s, 3H, CH_3), 0.86 (s, 3H, CH_3), 0.91 (s, 3H, CH_3), 0.94 (s, 3H, CH_3), 1.05 (s, 3H, CH_3), 1.20 (d, $J = 7.0 \text{ Hz}$, 3H, CH_3), 1.21 (d, $J = 7.0 \text{ Hz}$, 3H, CH_3), 2.05 (s, 3H, OCOCH_3), 2.10 (s, 3H, OCOCH_3), 2.15 (dd, $J = 18.6 \text{ Hz}$, 1H, $\text{C}^{22}\text{H}^{\text{F}}$), 2.47 (d, $J = 18.6 \text{ Hz}$, 1H, $\text{C}^{22}\text{H}^{\text{F}}$), 2.48 (ddd, $J = 13.4 \text{ Hz}$, $J = 4.1 \text{ Hz}$, $J' = 2.7 \text{ Hz}$, 1H, $\text{C}^{16}\text{H}^{\text{F}}$), 2.67 (dd, $J = 12.6 \text{ Hz}$, $J = 3.3 \text{ Hz}$, 1H, $\text{C}^{13}\text{H}^{\text{F}}$), 3.19 (sept., $J = 7.0 \text{ Hz}$, 1H, C^{20}H), 4.49 (dd, $J = 11.0 \text{ Hz}$, $J = 5.3 \text{ Hz}$, 1H, $\text{C}^3\text{H}^{\text{F}}$), 5.70 (d, $J = 5.5 \text{ Hz}$, 1H, OCH_2O), 5.79 (d, $J = 5.5 \text{ Hz}$, 1H, OCH_2O). EIMS m/z 584 (M^+ , 30), 554 (11), 541 (23), 512 (44), 481 (48), 467 (26), 452 (49), 409 (77), 391 (11), 321 (100), 249 (59), 203 (33), 189 (25). Anal. ($\text{C}_{35}\text{H}_{52}\text{O}_7$) C, H.

21,22-Dioxolup-18-ene-3 β ,28-diyl Diacetate (4a). A solution of ketone diacetate **3a** (2 g , 3.7 mmol) and SeO_2 (1.6 g , 14.4 mmol) in dioxane (40 mL), AcOH (20 mL), and Ac_2O (2

mL) was heated under reflux until reaction was complete by TLC (PhMe/Et₂O 10:1). After cooling, precipitated selenium was removed by filtration and the filtrate was poured slowly into an excess of vigorously stirred water. The red-orange precipitate was filtered under reduced pressure, washed carefully with H₂O, and air-dried. The crude product was dissolved in CHCl₃ and the solution was filtered through a column of alumina. The column was eluted with CHCl₃ and the filtrate was evaporated under reduced pressure. The residue was crystallized from MeOAc to afford **4a** as pale-orange crystals (1.45 g, 82%, mp 267–270 °C): [α]_D –127° (c 0.32); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 s, 3H, CH₃, 0.94 (s, 3H, CH₃), 0.97 (s, 3H, CH₃), 1.18 (s, 3H, CH₃), 1.24 (d, *J* = 7.0 Hz, 3H, CH₃), 1.26 (d, *J* = 7.0 Hz, 3H, CH₃), 1.91 (s, 3H, OCOCH₃), 2.06 (s, 3H, OCOCH₃), 3.12 (dd, *J* = 12.5 Hz, *J* = 3.5 Hz, 1H, C¹³H^F), 3.36 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 4.02 (d, *J* = 11.0 Hz, 1H, C²⁸H^F), 4.49 (dd, *J* = 11.0 Hz, *J* = 5.5 Hz, 1H, C³H^F), 4.84 (d, *J* = 11.0 Hz, C²⁸H^F). Ref.¹⁶ mp 269–271 °C, [α]_D –136° (c 0.6).

Methyl β -Acetoxy-21,22-dioxolup-18-en-28-oate (4b). Ketomethyl ester **3d** (500 mg, 0.98 mmol) was oxidized with SeO₂ (400 mg, 3.6 mmol) in a mixture of dioxane (10 mL), AcOH (5 mL), and Ac₂O (0.5 mL) in the same manner as in the preparation of diketone diacetate **4a**. Crystallization from dimethyl carbonate afforded **4b** as pale-orange needles (387 mg, 73%, mp 228–234 °C dec): [α]_D –100° (c 0.43); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.92 (s, 3H, CH₃), 0.97 (s, 3H, CH₃), 1.06 (s, 3H, CH₃), 1.26 (d, *J* = 7.0 Hz, 3H, CH₃), 1.29 (d, *J* = 7.0 Hz, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.54 (ddd, *J* = 13.5 Hz, *J* = 4.4 Hz, *J*' = 2.2 Hz, 1H, C¹⁶H^F), 2.78 (dd, *J* = 12.7 Hz, *J* = 3.3 Hz, 1H, C¹³H^F), 3.36 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 3.72 (s, 3H, OCH₃), 4.49 (dd, *J* = 11.2 Hz, *J* = 5.3 Hz, 1H, C³H^F); EIMS *m/z* 540 (M⁺, 1), 525 (1), 512 (3), 501 (1), 484 (100), 469 (37), 279 (3), 217 (4), 203 (7), 191 (17). Anal. (C₃₃H₄₈O₆) C, H.

Pivaloyloxymethyl β -Acetoxy-21,22-dioxolup-18-en-28-oate (4c). The keto-Pom ester **3e** (200 mg, 0.32 mmol) was oxidized with SeO₂ (160 mg, 1.4 mmol) in dioxane (4 mL), AcOH (2 mL), and Ac₂O (0.2 mL) in the same manner as in the preparation of diketone diacetate **4a**. Lyophilization from benzene afforded **4c** as a pale-orange powder (145 mg, 71%, mp 104–108 °C): [α]_D –135° (c 0.43); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.93 (s, 3H, CH₃), 0.97 (s, 3H, CH₃), 1.09 (s, 3H, CH₃), 1.19 (s, 9H, C(CH₃)₃), 1.26 (d, *J* = 7.0 Hz, 3H, CH₃), 1.26 (d, *J* = 7.0 Hz, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.54 (ddd, *J* = 13.5 Hz, *J* = 4.5 Hz, *J*' = 2.2 Hz, 1H, C¹⁶H^F), 2.80 (dd, *J* = 12.4 Hz, *J* = 3.5 Hz, 1H, C¹³H^F), 3.34 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 5.55 (d, *J* = 5.4 Hz, 1H, OCH₂O), 5.91 (d, *J* = 5.4 Hz, 1H, OCH₂O); EIMS *m/z* 640 (M⁺, 2), 610 (2), 582 (2), 565 (1), 550 (1), 542 (1), 506 (1), 498 (45), 481 (6), 470 (100), 455 (12), 439 (9), 217 (6), 203 (9), 189 (12). Anal. (C₃₈H₅₆O₈) C, H.

Acetoxymethyl β -Acetoxy-21,22-dioxolup-18-ene-28-oate (4d). Keto-Acm ester **3f** (250 mg, 0.43 mmol) was oxidized with SeO₂ (200 mg, 1.8 mmol) in dioxane (5 mL), AcOH (2.5 mL), and Ac₂O (0.25 mL) in the same manner as in the preparation of diketone diacetate **4a**. Crystallization from butanone afforded **4d** as pale-orange needles (176 mg, 69%, mp 227–228 °C): [α]_D –177° (c 0.43); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.92 (s, 3H, CH₃), 0.97 (s, 3H, CH₃), 1.07 (s, 3H, CH₃), 1.26 (d, *J* = 7.0 Hz, 3H, CH₃), 1.27 (d, *J* = 7.0 Hz, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.09 (s, 3H, OCOCH₃), 2.55 (ddd, *J* = 13.7 Hz, *J* = 4.5 Hz, *J*' = 2.4 Hz, 1H, C¹⁶H^F), 2.79 (dd, *J* = 12.6 Hz, *J* = 3.4 Hz, 1H, C¹³H^F), 3.35 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 4.49 (dd, *J* = 11.1 Hz, *J*' = 5.3 Hz, 1H, C³H^F), 5.62 (d, *J* = 5.5 Hz, 1H, OCH₂O), 5.82 (d, *J* = 5.5 Hz, 1H, OCH₂O); EIMS *m/z* 598 (M⁺, 8), 568 (2), 540 (10), 498 (40), 470 (100), 455 (18), 439 (6), 285 (5), 259 (5), 243 (10), 217 (20), 203 (29), 190 (46). Anal. (C₃₅H₅₀O₈) C, H.

18,19,21-Trioxo-18,19-secolupan- β ,28-diyl Diacetate (5a). A solution of ketone diacetate **3a** (500 mg, 0.93 mmol) in EtOAc (21 mL) was added to a mixture of Ru(IV)O₂·H₂O (15 mg, 0.11 mmol), NaIO₄ (1.3 g, 6.1 mmol), H₂O (18 mL), and CF₃COOH (0.5 mL). The biphasic mixture was stirred

vigorously at room temperature for 4 h, at which time reaction was complete by TLC (PhMe/Et₂O 6:1). EtOH was added, the mixture was filtered, and the organic layer was chromatographed on a short SiO₂ column (EtOAc). The eluate was evaporated under reduced pressure and the residue was crystallized from Me₂CO to afford **5a** as gold petals (339 mg, 64%, mp 226–228 °C): [α]_D +71° (c 0.39); ¹H NMR δ 0.84 (s, 3H, CH₃), 0.85 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 0.92 (s, 3H, CH₃), 1.13 (s, 3H, CH₃), 1.13 (d, *J* = 6.9 Hz, 3H, CH₃), 1.16 (d, *J* = 6.9 Hz, 3H, CH₃), 1.84 (ddd, *J* = 13.9 Hz, *J* = 4.4 Hz, *J*' = 2.2 Hz, 1H, C¹⁶H^F), 2.05 (s, 6H, 2 OCOCH₃), 2.31 (td, *J* = 13.9 Hz, *J* = 13.9 Hz, *J*' = 4.6 Hz, 1H, C¹⁶H^F), 2.68 (dd, *J* = 11.6 Hz, *J* = 3.3 Hz, 1H, C¹³H^F), 2.45 (d, *J* = 16.6 Hz, 1H, C²²H^F), 3.25 (d, *J* = 16.6 Hz, 1H, C²²H^F), 3.38 (sept., *J* = 6.9 Hz, 1H, C²⁰H), 4.20 (d, *J* = 11.3 Hz, 1H, C²⁸H^F), 4.48 (d, *J* = 11.3 Hz, 1H, C²⁸H^F), 4.48 (dd, *J* ≈ 10 Hz, *J* ≈ 6 Hz, 1H, C³H^F); EIMS *m/z* 572 (M⁺, 0.2), 557 (0.4), 501 (15), 459 (16), 441 (53), 399 (8), 381 (32), 371 (15), 353 (1), 339 (1), 215 (6), 201 (17), 189 (50), 71 (100). Anal. (C₃₄H₅₂O₇) C, H.

Methyl β -Acetoxy-18,19,21-trioxo-18,19-secolupan-28-oate (5b). Ketomethyl ester **3d** (400 mg; 0.76 mmol) was oxidized with Ru(VIII)O₄ (from Ru(IV)O₂·H₂O; 13 mg, 0.1 mmol) and NaIO₄ (1.1 g) in EtOAc (18 mL), H₂O (15 mL), and CF₃COOH (0.4 mL) in the same manner as in the preparation of triketone diacetate **5a**. Crystallization from MeOH afforded **5b** as yellow petals (259 mg, 61%, mp 173–175 °C): [α]_D +43° (c 0.45); ¹H NMR δ 0.82 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.85 (s, 3H, CH₃), 0.89 (s, 3H, CH₃), 1.07 (s, 3H, CH₃), 1.12 (d, *J* = 7.0 Hz, 3H, CH₃), 1.14 (d, *J* = 7.0 Hz, 3H, CH₃), 2.04 (s, 3H, OCOCH₃), 2.87 (d, *J* = 16.5 Hz, 1H, C²²H^F), 2.99 (dd, *J* = 11.9 Hz, *J* = 3.5 Hz, 1H, C¹³H^F), 3.15 (d, *J* = 16.5 Hz, 1H, C²²H^F), 3.36 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 3.78 (s, 3H, OCH₃), 4.47 (dd, *J* = 11.0 Hz, *J* = 5.4 Hz, 1H, C³H^F); EIMS *m/z* 558 (M⁺, 4), 527 (1), 487 (17), 444 (4), 427 (98), 395 (6), 367 (6), 277 (5), 249 (8), 231 (8), 215 (11), 201 (32), 189 (100). Anal. (C₃₃H₅₀O₇) C, H.

(Pivaloyloxy)methyl β -Acetoxy-18,19,21-trioxo-18,19-secolupan-28-oate (5c). Keto-Pom ester **3e** (400 mg, 0.64 mmol) was oxidized with Ru(VIII)O₄ (from Ru(IV)O₂·H₂O; 13 mg, 0.1 mmol) and NaIO₄ (2.1 g) in EtOAc (16 mL), H₂O (14 mL), and CF₃COOH (0.4 mL) in the same manner as in the preparation of triketone diacetate **5a**. Crystallization from MeOH afforded **5c** as yellow petals (273 mg, 65%, mp 152–154 °C): [α]_D +40° (c 0.38); ¹H NMR δ 0.81 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.89 (s, 3H, CH₃), 1.08 (s, 3H, CH₃), 1.11 (d, *J* = 7.0 Hz, 3H, C³⁰H₃), 1.14 (d, *J* = 7.0 Hz, 3H, C³⁰H₃), 1.22 (s, 9H, C(CH₃)₃), 2.04 (s, 3H, OCOCH₃), 2.36 (br. m, 1H, C¹⁶H^F), 2.88 (d, *J* = 16.8 Hz, 1H, C²²H^F), 3.06 (dd, *J* = 11.9 Hz, *J* = 3.5 Hz, 1H, C¹³H^F), 3.18 (d, *J* = 16.9 Hz, 1H, C²²H^F), 3.35 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 4.47 (dd, *J* = 11.0 Hz, *J* = 5.5 Hz, 1H, C³H^F); 5.75 (d, *J* = 5.5 Hz, 1H, OCH₂O), 5.85 (d, *J* = 5.5 Hz, 1H, OCH₂O); EIMS *m/z* 658 (M⁺, 1), 612 (2), 598 (7), 584 (2), 544 (3), 498 (16), 484 (6), 470 (32), 438 (7), 413 (23), 349 (13), 249 (8), 235 (20), 217 (8), 203 (20), 189 (100). Anal. (C₃₈H₅₈O₉) C, H.

Acetoxymethyl β -Acetoxy-18,19,21-trioxo-18,19-secolupan-28-oate (5d). Keto-Acm ester **3f** (400 mg, 0.68 mmol) was oxidized with Ru(VIII)O₄ (from Ru(IV)O₂·H₂O; 13 mg, 0.1 mmol) and NaIO₄ (2.1 g) in EtOAc (16 mL), H₂O (14 mL), and CF₃COOH (0.4 mL) in the same manner as in the preparation of the triketone diacetate **5a**. Crystallization from MeOH afforded **5d** as yellow petals (273 mg, 65%, mp 215–235 °C dec): [α]_D +32° (c 0.44); ¹H NMR δ 0.81 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 1.08 (s, 3H, CH₃), 1.11 (d, *J* = 7.0 Hz, 3H, CH₃), 1.14 (d, *J* = 7.0 Hz, 3H, CH₃), 2.04 (s, 3H, CH₃), 2.12 (s, 3H, 2 OCOCH₃), 2.37 (br. m, 1H, C¹⁶H^F), 2.85 (d, *J* = 16.8 Hz, 1H, C²²H^F), 3.06 (dd, *J* = 11.9 Hz, *J* = 3.4 Hz, 1H, C¹³H^F), 3.21 (d, *J* = 16.8 Hz, 1H, C²²H^F), 3.35 (sept., *J* = 7.0 Hz, 1H, C²⁰H), 4.47 (dd, *J* = 11.0 Hz, *J* = 5.5 Hz, 1H, C³H^F), 5.76 (d, *J* = 5.5 Hz, 1H, OCH₂O), 5.83 (d, *J* = 5.5 Hz, 1H, OCH₂O); EIMS *m/z* 616 (M⁺, 1), 574 (1), 557 (1), 515 (4), 485 (5), 473 (9), 455 (8), 413 (25), 395 (18), 367 (15), 275 (3), 249 (11), 215 (8), 189 (100). Anal. (C₃₅H₅₂O₉) C, H.

18,19,21,22-Tetraoxo-18,19-secolupan-3 β ,28-diyl Diacetate (6). A solution of diketone diacetate **4a** (500 mg, 0.93 mmol) in EtOAc (20 mL) and MeCN (5 mL) was added to a mixture of Ru(IV)O₂·H₂O (20 mg, 0.15 mmol), NaIO₄ (3.5 g, 16.4 mmol), H₂O (18 mL), and CF₃COOH (0.5 mL). The biphasic mixture was stirred vigorously at room temperature for 20 h, when TLC (PhMe/EtOAc 20:1) indicated complete reaction. EtOH was added, the mixture was filtered, the phases were separated, and the organic layer was dried and evaporated under a reduced pressure. The residue (643 mg), which according to ¹H NMR analysis contained tetraketone **6** and β -keto acid **8a** in a ratio of approximately 1:1, was chromatographed on SiO₂ (50 g) in PhMe/EtOAc (20:1). Crystallization from Me₂CO/isopentane afforded pure **6** as yellow-orange crystals (190 mg, 36%, mp 202–205 °C): [α]_D +37° (c 0.27); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.89 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 1.13 (s, 3H, CH₃), 1.21 (d, *J* = 6.9 Hz, 3H, CH₃), 1.22 (d, *J* = 6.9 Hz, 3H, CH₃), 2.02 (s, 3H, OCOCH₃), 2.05 (s, 3H, OCOCH₃), 2.43 (br. m, 1H, C¹⁶H^F), 2.84 (dd, *J* = 11.6 Hz, *J*' = 3.5 Hz, 1H, C¹³H^F), 3.41 (sept, *J* = 7.0 Hz, 1H, C²⁰H), 4.48 (m, $\Sigma J \approx 15$ Hz, 1H, C³H^F), 4.48 (d, *J* = 11.1 Hz, 1H, C²⁸H^F), 4.77 (d, *J* = 11.1 Hz, 1H, C²⁸H^F); EIMS *m/z* 586 (M⁺, 3), 544 (2), 526 (4), 514 (33), 513 (9), 498 (2), 487 (78), 474 (12), 459 (17), 444 (11), 427 (7), 417 (6), 400 (27), 383 (11), 367 (8), 357 (31), 339 (28), 322 (12), 297 (10), 276 (12), 249 (20), 229 (13), 216 (17), 203 (50), 189 (100). Anal. (C₃₄H₅₀O₈) C, H.

3 β ,28-Diacetoxy-18-oxo-19,20,29,30-tetranorlupane-21-oxo Acid (7a). A solution of triketone **5a** (300 mg, 0.52 mmol) and AcOOH (5 mL of a 32% solution in glacial acetic acid) in CHCl₃ (40 mL) was stirred at room temperature for 24 h, when TLC (PhMe/Et₂O 6:1) indicated complete reaction. The colorless reaction mixture was diluted with cold H₂O and was extracted with CHCl₃. The combined organic layers were washed successively with 5% aqueous KI solution (400 mL), saturated aqueous sodium sulfite solution (200 mL), and brine (2 × 200 mL) and then dried and evaporated. According to ¹H NMR analysis the resulting pale-yellow oil (268 mg) was a mixture of the keto acid **7a** and spiro lactone **14**¹⁹ in a ratio of approximately 4:1. Preparative TLC (CHCl₃/EtOAc/AcOH 100:10:1), followed by crystallization from Et₂O/hexane, afforded **7a** as a white crystalline powder (165 mg, 61%, mp 152–155 °C and 185–189 °C dec): [α]_D +26° (c 0.30); ¹H NMR δ 0.84 (s, 3H, CH₃), 0.85 (s, 3H, CH₃), 0.87 (s, 3H, CH₃), 0.90 (s, 3Hm CH₃), 1.14 (s, 3H, CH₃), 2.03 (s, 3H, OCOCH₃), 2.05 (s, 3H, OCOCH₃), 2.53 (d, *J* = 15.6 Hz, 1H, C²²H^F), 2.60 (d, *J* = 15.6 Hz, 1H, C²²H^F), 2.81 (dd, *J* = 11.9 Hz, *J*' = 3.5 Hz, 1H, C¹³H^F), 4.20 (d, *J* = 11.4 Hz, 1H, C²⁸H^F), 4.48 (dd, *J* = 11.0 Hz, *J*' = 5.3 Hz, 1H, C³H^F), 4.60 (d, *J* = 11.4 Hz, 1H, C²⁸H^F); EIMS *m/z* 518 (M⁺, 3), 503 (1), 486 (2), 458 (100), 443 (38), 430 (6), 415 (60), 398 (27), 383 (16), 355 (17), 323 (7), 255 (32), 241 (16), 204 (15), 189 (15). Anal. (C₃₀H₄₆O₇) C, H.

Methyl 3 β ,28-Diacetoxy-18-oxo-19,20,29,30-tetranorlupane-21-oate (7b). This compound was obtained by esterification of keto acid **7a** with diazomethane (mp 209–211 °C, MeOH): [α]_D +52° (c 0.46); ¹H NMR δ 0.84 (s, 3H, CH₃), 0.85 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 0.91 (s, 3H, CH₃), 1.13 (s, 3H, CH₃), 2.03 (s, 3H, OCOCH₃), 2.05 (s, 3H, OCOCH₃), 2.43 (d, *J* = 15.9 Hz, 1H, C²²H^F), 2.66 (d, *J* = 15.9 Hz, 1H, C²²H^F), 2.75 (dd, *J* \approx 12 Hz, *J*' \approx 4 Hz, 1H, C¹³H^F), 3.66 (s, 3H, OCH₃), 4.19 (d, *J* \approx 11 Hz, 1H, C²⁸H^F), 4.48 (dd, *J* \approx 10 Hz, *J*' \approx 6 Hz, 1H, C³H^F), 4.56 (d, *J* \approx 11 Hz, 1H, C²⁸H^F); EIMS *m/z* 532 (M⁺, 3), 517 (1), 501 (1), 472 (40), 457 (11), 441 (4), 429 (17), 412 (3), 397 (4), 381 (3), 369 (2), 339 (3), 269 (91), 255 (23), 204 (14), 195 (30), 189 (100). Anal. (C₃₁H₄₈O₇) C, H.

Methyl 3 β -Acetoxy-18-oxo-19,20,28,29,30-pentanorlupane-21-oate (7c). A suspension of methyl keto ester **7b** (140 mg, 0.27 mmol) in a solution of KOH (140 mg, 2.43 mmol) in EtOH (7.5 mL) was refluxed for 3 h, at which time all starting material had dissolved. After cooling, the reaction mixture was poured into H₂O (50 mL). The resulting solution was acidified with 10% aqueous HCl (2 mL) and was extracted twice with Et₂O. The combined organic extracts were washed with H₂O, dried, and evaporated. The residue (102 mg) was treated with

diazomethane and then acetylated with Ac₂O (2 mL) in pyridine (2 mL). The usual workup gave a white foamy residue. Purification by preparative TLC (PhMe/Et₂O 10:1) and crystallization from CHCl₃/MeOH afforded **7c** (76 mg, 58%, mp 192–194 °C): [α]_D +11° (c 0.50); ¹H NMR δ 0.79 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.85 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 1.12 (s, 3H, CH₃), 2.04 (s, 3H, OCOCH₃), 2.13 (dd, *J* = 16.0 Hz, *J*' = 5.5 Hz, 1H, C²²H^F), 2.56 (dd, *J* = 12.4 Hz, *J*' = 3.7 Hz, 1H, C¹³H^F), 2.73 (dd, *J* = 16.0 Hz, *J*' = 7.3 Hz, 1H, C²²H^F), 2.78 (br. m, $\Sigma J \approx 28$ Hz, 1H, C¹⁷H), 3.67 (s, 3H, OCH₃), 4.48 (dd, *J* = 11.2 Hz, *J*' = 5.3 Hz, 1H, C³H^F). Ref.¹⁹ mp 193–195 °C, [α]_D +12°.

28-Methyl-21-hydrogen 3 β -Acetoxy-18-oxo-19,20,29,30-tetranorlupane-21,28-dioate (7d). Triketomethyl ester **5b** (200 mg, 0.36 mmol) was oxidized with AcOOH (3 mL of a 32% solution in glacial acetic acid) in CHCl₃ (30 mL) in the same manner as in the preparation of the keto acid **7a**. Crystallization from Et₂O afforded **7d** as small white crystals (129 mg, 71%, mp 177–180 °C): [α]_D +64° (c 0.44); ¹H NMR δ 0.82 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.89 (s, 3H, CH₃), 1.08 (s, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.46 (ddd, *J* = 14.0 Hz, *J*' = 4.1 Hz, *J*'' = 2.7 Hz, 1H, C¹⁶H^F), 2.62 (d, *J* = 16.3 Hz, 1H, C²²H^F), 2.85 (dd, *J* = 12.0 Hz, *J*' = 3.5 Hz, 1H, C¹³H^F), 2.85 (d, *J* = 16.3 Hz, 1H, C²²H^F), 3.73 (s, 3H, OCH₃), 4.47 (dd, *J* = 11.0 Hz, *J*' = 5.3 Hz, 1H, C³H^F); EIMS *m/z* 504 (M⁺, 2), 461 (1), 444 (20), 429 (8), 401 (10), 385 (1), 335 (3), 309 (4), 264 (7), 254 (6), 241 (59), 228 (8), 223 (30), 216 (8), 204 (15), 197 (10), 189 (100). Anal. (C₂₉H₄₄O₇) C, H.

Dimethyl 3 β -Acetoxy-18-oxo-19,20,29,30-tetranorlupane-21,28-dioate (7e). This compound was obtained by reaction of acid **7d** with diazomethane (mp 127–129 °C, MeOH): [α]_D +74° (c 0.40); ¹H NMR δ 0.83 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.89 (s, 3H, CH₃), 1.07 (s, 3H, CH₃), 2.04 (s, 3H, OCOCH₃), 2.43 (ddd, *J* = 13.9 Hz, *J*' = 4.2 Hz, *J*'' = 2.7 Hz, 1H, C¹⁶H^F), 2.60 (d, *J* = 16.0 Hz, 1H, C²²H^F), 2.81 (d, *J* = 16.0 Hz, 1H, C²²H^F), 2.83 (dd, *J* = 12.0 Hz, *J*' = 3.6 Hz, 1H, C¹³H^F), 3.66 (s, 3H, OCH₃), 3.75 (s, 3H, OCH₃), 4.47 (dd, *J* = 11.0 Hz, *J*' = 5.5 Hz, 1H, C³H^F); EIMS *m/z* 518 (M⁺, 26), 458 (100), 443 (52), 427 (39), 415 (66), 353 (27), 255 (61), 223 (27), 189 (35). Anal. (C₃₀H₄₆O₇) C, H.

21-Methyl-28-(pivaloyloxy)methyl 3 β -Acetoxy-18-oxo-19,20,29,30-tetranorlupane-21,28-dioate (7f). The triketo-Pom ester **5c** (200 mg, 0.30 mmol) was oxidized with AcOOH (10 mL of a 32% solution in glacial acetic acid) in CHCl₃ (30 mL) in the same manner as in the preparation of keto acid **7a**. The resulting colorless solid (157 mg) contained a polar compound as the major component and a less polar impurity according to TLC (PhMe/Et₂O 6:1). Crude methyl ester **7f** was obtained by treatment with diazomethane. Preparative HPLC (15% EtOAc in hexane) and crystallization from MeOH afforded pure **7f** (83 mg, 44%, mp 153–156 °C): [α]_D +63° (c 0.30); ¹H NMR δ 0.82 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.89 (s, 3H, CH₃), 1.09 (s, 3H, CH₃), 1.21 (s, 9H, C(CH₃)₃), 2.04 (s, 3H, OCOCH₃), 2.42 (ddd, *J* = 13.9 Hz, *J*' = 4.2 Hz, *J*'' = 2.7 Hz, 1H, C¹⁶H^F), 2.61 (d, *J* = 16.2 Hz, 1H, C²²H^F), 2.82 (d, *J* = 16.2 Hz, 1H, C²²H^F), 2.90 (dd, *J* = 12.1 Hz, *J*' = 3.7 Hz, 1H, C¹³H^F), 3.66 (s, 3H, OCH₃), 4.47 (dd, *J* = 11.0 Hz, *J*' = 5.5 Hz, 1H, C³H^F), 5.69 (d, *J* = 5.5 Hz, 1H, OCH₂O), 5.87 (d, *J* = 5.5 Hz, 1H, OCH₂O); EIMS *m/z* 618 (M⁺, 4), 558 (69), 543 (16), 515 (21), 486 (26), 427 (65), 383 (29), 355 (100), 337 (21), 269 (29), 223 (27), 189 (29). Anal. (C₃₅H₅₄O₉) C, H.

28-Acetoxyethyl-21-methyl 3 β -Acetoxy-18-oxo-19,20,29,30-tetranorlupane-21,28-dioate (7g). Triketo-Acm ester **5d** (200 mg, 0.32 mmol) was oxidized with AcOOH (10 mL of a 32% solution in glacial acetic acid) in CHCl₃ (30 mL) in the same manner as in the preparation of the keto acid **7a**. The resulting colorless solid (143 mg) contained a polar compound as the major component and a less polar impurity according to TLC (PhMe/Et₂O 6:1). Crude methyl ester **7g** was obtained by treatment with diazomethane. Preparative HPLC (25% EtOAc in hexane) and crystallization from MeOH afforded pure **7g** (73 mg, 39%, mp 127–129 °C): [α]_D +66° (c 0.27); ¹H NMR δ 0.82 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.84 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 1.08 (s, 3H, CH₃), 2.04 (s, 3H,

OCOC₂H₅), 2.11 (s, 3H, OCOCH₃), 2.42 (ddd, *J* = 13.9 Hz, *J*' = 4.2 Hz, *J*'' = 2.7 Hz, 1H, C¹⁶H^β), 2.61 (d, *J* = 16.2 Hz, 1H, C²²H^β), 2.83 (d, *J* = 16.2 Hz, 1H, C²²H^β), 2.91 (dd, *J* = 12.1 Hz, *J*' = 3.5 Hz, 1H, C¹³H^β), 3.66 (s, 3H, OCH₃), 4.47 (dd, *J* = 11.0 Hz, *J*' = 5.5 Hz, 1H, C³H^β), 5.76 (d, *J* = 5.6 Hz, 1H, OCH₂O), 5.83 (d, *J* = 5.6 Hz, 1H, OCH₂O); EIMS *m/z* 576 (M⁺, 7), 552 (3), 528 (3), 516 (100), 501 (22), 473 (42), 427 (47), 383 (22), 353 (25), 313 (13), 223 (20), 189 (28). Anal. (C₃₂H₄₈O₉) C, H.

3β,28-Diacetoxy-18-oxo-19,20,21,29,30-pentanoluplan-22-oic Acid (8a). From Tetraketone **6**. A solution of **6** (102 mg, 0.17 mmol) and AcOOH (6 mL of a 32% solution in glacial acetic acid) in CHCl₃ (15 mL) was stirred at room temperature for 17 h when TLC (PhMe/Et₂O 6:1) indicated complete reaction. The colorless reaction mixture was diluted with cold H₂O and was extracted with chloroform (3 × 20 mL). The combined extracts were washed successively with 5% aqueous KI, saturated aqueous Na₂SO₃, and brine, dried, and evaporated. The resulting colorless solid (96 mg) contained a polar compound as the major component according to TLC (PhMe/Et₂O 6:1). Preparative TLC (CHCl₃/EtOAc/AcOH 100:10:1) and crystallization from CH₂Cl₂/Et₂O afforded pure **8a** as small white needles (36 mg, 41%, mp 137–140 °C dec): [α]_D +40° (*c* 0.37); ¹H NMR δ 0.85 (s, 3 H, CH₃), 0.86 (s, 3 H, CH₃), 0.91 (s, 6 H, CH₃), 1.14 (s, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.06 (s, 3H, OCOCH₃), 2.79 (dd, *J* = 11.7 Hz, *J*' = 3.6 Hz, 1H, C¹³H^β), 4.46 (d, *J* ≈ 1 Hz, 1H, C²⁸H^β), 4.48 (dd, *J* ≈ 11 Hz, *J*' ≈ 6 Hz, 1H, C³H^β), 4.64 (d, *J* ≈ 11 Hz, 1H, C²⁸H^β); EIMS *m/z* 444 (M⁺ - 60, 1), 416 (3), 414 (3), 400 (22), 382 (2), 354 (6), 340 (15), 325 (10), 297 (9), 291 (7), 281 (7), 278 (9), 276 (31), 271 (7), 264 (27), 257 (7), 231 (7), 216 (33), 204 (40), 189 (100). Anal. (C₂₉H₄₄O₇) C, H.

From Anhydride 9a. A suspension of **9a** (500 mg, 0.88 mmol) in EtOAc (20 mL) and MeCN (5 mL) was added to a mixture of Ru(IV)O₂·H₂O (40 mg, 0.30 mmol), NaIO₄ (7.5 g, 35.1 mmol), H₂O (18 mL) and CF₃COOH (0.5 mL). The biphasic mixture was stirred vigorously at room temperature for 6 d, after which time TLC (PhMe/EtOAc 20:1) indicated complete reaction. EtOH was added, the mixture was filtered, and the organic layer was dried and evaporated under reduced pressure. The white residue (643 mg) was crystallized from CH₂Cl₂/Et₂O to afford **8a** as small white needles (237 mg, 54%, mp 138–140 °C): [α]_D +40° (*c* 0.37). This material was identical to the sample obtained from the procedure described above.

Methyl 3β,28-Diacetoxy-18-oxo-19,20,21,29,30-pentanoluplan-22-oate (8b). A solution of diene diacetate **10** (500 mg, 0.95 mmol) in EtOAc (15 mL) and MeCN (5 mL) was added to a mixture of Ru(IV)O₂·H₂O (20 mg, 0.15 mmol), NaIO₄ (3.5 g, 16.4 mmol), H₂O (15 mL), and CF₃COOH (0.5 mL). The biphasic mixture was stirred vigorously at room temperature for 60 h, after which time TLC (PhMe/Et₂O 10:1) indicated complete reaction. EtOH ethanol was added, the mixture was filtered, and the organic layer was separated and filtered through a short column of silica gel. The column was eluted with EtOAc and the eluate was evaporated under reduced pressure. The resulting red-brown solid (437 mg) contained, according to TLC (PhMe/Et₂O 6:1), a polar compound as the major component and a less polar impurity. The crude β-ketomethyl ester **8b** was obtained by treatment with diazomethane. Preparative TLC (PhMe/Et₂O 10:1) and crystallization from CHCl₃/MeOH afforded pure **8b** (232 mg, 47%, mp 255–258 °C dec): [α]_D +68° (*c* 0.26); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 0.94 (s, 3H, CH₃), 1.13 (s, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.06 (s, 3H, OCOCH₃), 2.45 (m, Σ*J* = 34 Hz, 1H, C¹⁶H^β), 2.61 (dd, *J* = 11.7 Hz, *J*' = 3.6 Hz, 1H, C¹³H^β), 3.77 (s, 3H, OCH₃), 4.44 (d, *J* = 11.2 Hz, 1H, C²⁸H^β), 4.48 (dd, *J* ≈ 11 Hz, *J*' ≈ 6 Hz, 1H, C³H^β), 4.56 (d, *J* = 11.2 Hz, 1H, C²⁸H^β); EIMS *m/z* 487 (M⁺ - 31, 3), 458 (45), 443 (15), 440 (3), 430 (9), 415 (21), 398 (6), 389 (5), 376 (6), 370 (7), 349 (4), 323 (4), 255 (95), 241 (23), 223 (23), 204 (18), 199 (18), 189 (100). Anal. (C₃₀H₄₆O₇) C, H.

Acetoxymethyl 3β,28-Diacetoxy-18-oxo-19,20,21,29,30-pentanoluplan-22-oate (8d). Well-powdered Ag₂CO₃ (83 mg,

0.30 mmol) was added to the solution of β-keto acid **8a** (100 mg, 0.20 mmol) and bromomethyl acetate (34 mg, 0.22 mmol) in dry DMF (5 mL) and this heterogeneous mixture was stirred at room temperature for 2 d, when TLC (PhMe/Et₂O 6:1) indicated complete reaction. The reaction mixture was filtered, poured into cold H₂O (50 mL), and extracted with CHCl₃. The combined extracts were washed twice with brine, dried, and evaporated. The resulting gray oil (131 mg) was purified by preparative TLC (PhMe/Et₂O 5:1) and the product was crystallized from butanone to afford pure **8d** as white needles (45 mg, 39%, mp 234–236 °C): [α]_D +69° (*c* 0.46); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 0.93 (s, 3H, CH₃), 1.12 (s, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.05 (s, 3H, OCOCH₃), 2.13 (s, 3H, OCOCH₃), 2.44 (m, 1H, C¹⁶H^β), 2.60 (dd, *J* = 11.8 Hz, *J*' = 3.6 Hz, 1H, C¹³H^β), 4.43 (d, *J* = 11.2 Hz, 1H, C²⁸H^β), 4.48 (dd, *J* = 11.1 Hz, *J*' = 5.2 Hz, 1H, C³H^β), 4.56 (d, *J* = 11.2 Hz, C²⁸H^β), 5.79 (d, *J* = 5.5 Hz, 1H, OCH₂O), 5.80 (d, *J* = 5.5 Hz, 1H, OCH₂O); EIMS *m/z* 576 (M⁺, 2), 534 (2), 516 (100), 501 (25), 473 (32), 444 (16), 383 (14), 338 (13), 313 (30), 223 (27), 209 (13), 189 (52). Anal. (C₃₂H₄₈O₉) C, H.

Anhydride of 3β,28-Diacetoxy-21,22-secolup-18-ene-21,22-dioic Acid (9a). A solution of diketone diacetate **4a** (1 g, 1.81 mmol) and AcOOH (20 mL of a 32% solution in glacial acetic acid) in CHCl₃ (120 mL) was stirred at room temperature for 7 d when TLC (PhMe/Et₂O 6:1) indicated complete reaction. The colorless reaction mixture was diluted with cold H₂O and extracted with CHCl₃. The combined extracts were washed successively with 5% aqueous KI, saturated aqueous Na₂SO₃, and brine and then dried and evaporated. The resulting pale-yellow oil (1.2 g) was crystallized from CHCl₃/MeOH to afford **9a** as a white crystalline powder (875 mg, 85%, mp 306–309 °C): [α]_D +88° (*c* 0.45); ¹H NMR δ 0.86 (s, 6H, CH₃), 0.90 (s, 3H, CH₃), 0.91 (s, 3H, CH₃), 1.11 (s, 3H, CH₃), 1.15 (d, *J* = 6.7 Hz, 3H, CH₃), 1.31 (d, *J* = 7.0 Hz, 3H, CH₃), 2.02 (s, 3H, OCOCH₃), 2.05 (s, 3H, OCOCH₃), 2.53 (dt, *J* = 14.4 Hz, *J*' = 3.5 Hz, 1H, C¹⁶H^β), 2.72 (dd, *J* = 12.7 Hz, *J*' = 2.9 Hz, 1H, C¹³H^β), 3.26 (sept., *J* = 6.9 Hz, 1H, C²⁰H), 3.89 (d, *J* = 11.0 Hz, 1H, C²⁸H^β), 4.47 (dd, *J* = 11.3 Hz, *J*' = 5.0 Hz, 1H, C³H^β), 4.54 (d, *J* = 11.0 Hz, 1H, C²⁸H^β). Ref.¹⁸ mp 308–310 °C, [α]_D +87° (*c* 0.60).

Anhydride of 3β-Acetoxy-17β-methoxycarbonyl-28-nor-21,22-secolup-18-ene-21,22-dioic Acid (9b). Diketomethyl ester **4b** (500 mg, 0.93 mmol) was oxidized by treatment with AcOOH (10 mL of a 32% solution in glacial acetic acid) in CHCl₃ (55 mL) in the same manner as in the preparation of the anhydride **9a**. Crystallization from CHCl₃/MeOH afforded **9b** as small white crystals (355 mg, 69%, mp 231–237 °C dec): [α]_D +116° (*c* 0.49); ¹H NMR δ 0.85 (s, 3H, CH₃), 0.86 (s, 3H, CH₃), 0.90 (s, 3H, CH₃), 0.92 (s, 3H, CH₃), 1.12 (s, 3H, CH₃), 1.16 (d, *J* = 6.7 Hz, 3H, CH₃), 1.34 (d, *J* = 7.0 Hz, 3H, CH₃), 2.05 (s, 3H, OCOCH₃), 2.38 (ddd, *J* = 14.5 Hz, *J*' = 12.1 Hz, *J*'' = 3.7 Hz, 1H, C¹⁶H^β), 2.49 (ddd, *J* = 14.5 Hz, *J*' = 5.3 Hz, *J*'' = 4.0 Hz, 1H, C¹⁶H^β), 2.85 (dd, *J* = 12.6 Hz, *J*' = 3.0 Hz, C¹³H^β), 3.32 (sept., *J* = 6.9 Hz, 1H, C²⁰H), 3.76 (s, 3H, OCH₃), 4.47 (dd, *J* = 11.1 Hz, *J*' = 5.2 Hz, 1H, C³H^β); EIMS *m/z* 556 (M⁺, 7), 541 (4), 510 (1), 496 (7), 484 (5), 481 (3), 469 (7), 453 (9), 437 (5), 409 (2), 315 (1), 293 (10), 279 (8), 249 (8), 236 (10), 221 (9), 203 (23), 189 (100). Anal. (C₃₃H₄₈O₇) C, H.

3β-Hydroxy-19,20,21,22,28,29,30-heptanoluplan-18-one (11a). β-Keto acid **8a** (150 mg, 0.30 mmol) was added to a solution of KOH (160 mg, 2.86 mmol) in dioxane (5.3 mL) and H₂O (3.7 mL) and the mixture was refluxed for 3 h under Ar. All starting material had dissolved during this time. After cooling, the reaction mixture was poured into H₂O (50 mL); the resulting solution was acidified with 10% aqueous HCl (2 mL) and was extracted twice with Et₂O. The combined extracts were washed with H₂O, dried, and evaporated. The resulting white crystalline solid (96 mg) contained a polar compound by TLC (PhMe/Et₂O 1:1). This was purified by preparative TLC (PhMe/Et₂O 1:1) and crystallization from CHCl₃/MeOH to afford pure **11a** as a white crystalline powder (67 mg, 61%, mp 191–193 °C sublim): [α]_D +10° (*c* 0.24); ¹H NMR δ 0.77 (s, 3H, CH₃), 0.83 (s, 3H, CH₃), 0.87 (d, *J* = 0.9 Hz, 3H, CH₃),

0.97 (s, 3H, CH_3), 1.11 (s, 3H, CH_3), 2.16–2.34 (m, 2H, $C^{17}H_2$), 2.49 (dd, $J \approx 12$ Hz, $J' \approx 4$ Hz, 1H, $C^{13}HF$), 3.20 (dd, $J = 10.8$ Hz, $J' = 5.4$ Hz, 1H, C^3HF); EIMS m/z 346 (M^+ , 17), 328 (15), 313 (5), 310 (2), 295 (1), 285 (2), 234 (14), 222 (8), 216 (7), 207 (78), 204 (17), 189 (43), 135 (37), 121 (33), 111 (100). Anal. ($C_{23}H_{38}O_2$) C, H, N.

18-Oxo-19,20,21,22,28,29,30-heptanorlupan-3 β -yl Acetate (11b). This was obtained by acetylation of **11a** with Ac_2O in pyridine and the usual workup procedure (mp 215–218 °C, $CHCl_3/MeOH$): $[\alpha]_D +11^\circ$ (c 0.48); 1H NMR δ 0.83 (s, 3H, CH_3), 0.84 (s, 3H, CH_3), 0.85 (s, 3H, CH_3), 0.90 (s, 3H, CH_3), 1.11 (s, 3H, CH_3), 2.04 (s, 3H, $OCOCCH_3$), 2.16–2.35 (m, 2H, $C^{17}H_2$), 2.48 (dd, $J \approx 12$ Hz, $J' \approx 3$ Hz, 1H, $C^{13}HF$), 4.48 (dd, $J \approx 11$ Hz, $J' \approx 6$ Hz, 1H, C^3HF); EIMS m/z 388 (M^+ , 22), 373 (2), 370 (12), 328 (49), 313 (17), 310 (5), 295 (5), 285 (24), 276 (9), 264 (24), 259 (12), 246 (6), 216 (20), 204 (27), 189 (100), 111 (68). Anal. ($C_{25}H_{40}O_3$) C, H, N. Ref.¹⁵ mp 200–203 °C, $[\alpha]_D +22^\circ$.

18-Oxo-19,20,21,22,29,30-hexanorlup-17(28)-en-3 β -yl Acetate (12). A solution of β -keto acid **8a** (1 g 1.98 mmol) in diglyme (10 mL) was refluxed for 10 min, after which time TLC (PhMe/ Et_2O 6:1) indicated complete reaction. After cooling, the reaction mixture was poured into excess H_2O and this was extracted with $CHCl_3$. The combined extracts were washed with H_2O , dried, and evaporated. According to TLC (PhMe/ Et_2O 6:1) the resulting pale-yellow oil (1.5 g) was a mixture of three major components (heptanor ketone **11b**, methylene ketone **12**, and an unidentified compound) in the ratio of approximately 1:1:1. This mixture was separated by preparative HPLC (10% $EtOAc$ in hexane).

Pure 12 (72 mg, 9%, mp 268–269 °C, lyophilisate from benzene): $[\alpha]_D +32^\circ$ (c 0.37); 1H NMR δ 0.85 (s, 3H, CH_3), 0.86 (s, 3H, CH_3), 0.90 (s, 3H, CH_3), 0.91 (s, 3H, CH_3), 1.06 (s, 3H, CH_3), 2.05 (s, 3H, $OCOCCH_3$), 2.46 (dd, $J = 12$ Hz, $J' = 4$ Hz, 1H, $C^{13}HF$), 2.49–2.65 (br. m, 2H, $C^{16}H_2$), 4.49 (m, $\Sigma J = 16.5$ Hz, 1H, C^3HF), 5.06 (dt, $J = 1.2$ Hz, $J' = J'' = 2.1$ Hz, 1H, $C^{28}HF$), 5.72 (dt, $J = 0.8$ Hz, $J' = J'' = 2.0$ Hz, 1H, $C^{28}HF$); EIMS m/z 400 (M^+ , 48), 337 (100), 320 (38), 297 (24), 283 (25), 276 (97), 264 (63), 249 (24), 189 (19). Anal. ($C_{26}H_{40}O_3$) C, H.

Heptanor ketone acetate 11b (131 mg, 17%) was identical with an authentic sample.

17 α -Ethoxymethyl-18-oxo-19,20,21,22,28,29,30-heptanorlupan-3 β -yl Acetate (13b). A suspension of β -keto acid **8a** (120 mg, 0.24 mmol) in a solution of KOH (120 mg, 2.14 mmol) in $EtOH$ (6.3 mL) was refluxed for 3 h. All starting material had dissolved during this time. After cooling, the reaction mixture was poured into H_2O (50 mL) and the resulting solution was acidified with 10% aqueous HCl (2 mL). This was extracted twice with Et_2O . The combined extracts were washed with H_2O , dried, and evaporated. According to 1H NMR analysis, the resulting pale-yellow oil (78 mg) was a mixture of heptanor ketone **11a** and ethoxyheptanor ketone **13a** in a ratio of approximately 1:1. The residue was acetylated with Ac_2O (1.5 mL) in pyridine (1.5 mL). Usual workup gave a white foamy residue, which was fractionated by preparative HPLC (10% $EtOAc$ in hexane).

Heptanor ketone acetate 11b (14 mg, 15%, mp 216–219 °C, $CHCl_3/MeOH$): $[\alpha]_D +11^\circ$ (c 0.48), was identical to an authentic sample.

Ethoxyheptanor ketone acetate 13b (18 mg, 17%, mp 139–144 °C, $CHCl_3/MeOH$): $[\alpha]_D +23^\circ$ (c 0.32). 1H NMR δ 0.80 (s, 3H, CH_3), 0.85 (s, 6H, CH_3), 0.90 (s, 3H, CH_3), 1.10 (s, 3H, CH_3), 1.18 (t, $J = 7.0$ Hz, 3H, OCH_2CH_3), 2.05 (s, 3H, $OCOCCH_3$), 2.43–2.55 (m, 2H, $C^{13}H$ & $C^{17}H$), 3.28 (dd, $J = 9.6$ Hz, $J' = 7.5$ Hz, 1H, $C^{28}HF$), 3.40–3.58 (m, 2H, OCH_2CH_3), 3.77 (dd, $J = 9.6$ Hz, $J' = 5.1$ Hz, 1H, $C^{28}HF$), 4.48 (m, $\Sigma J = 16.5$ Hz, 1H, C^3HF); EIMS m/z 446 (M^+ , 49), 431 (1), 428 (1), 417 (3), 402 (7), 387 (4), 386 (4), 371 (7), 343 (7), 276 (6), 264 (5), 216 (7), 204 (8), 189 (47), 183 (77), 169 (68), 114 (100). Anal. ($C_{28}H_{46}O_4$) C, H.

3 β -Acetoxy-19,20,21,22,28,29,30-heptanor-17,18-secolupan-17,18-dioic Acid (15a). From Hydroxy Ketone **3b**. A solution of **3b** (500 mg, 1.00 mmol) in $EtOAc$ (10 mL), $MeOAc$ (10 mL), and $MeCN$ (5 mL) was added to a mixture of $Ru(IV)O_2 \cdot H_2O$ (20 mg, 0.15 mmol), $NaIO_4$ (3.5 g, 16.4 mmol), H_2O

(15 mL), and CF_3COOH (0.5 mL). The reaction mixture was stirred vigorously at room temperature for 3 d, after which time TLC ($CHCl_3/EtOAc/COH$ 100:10:1) indicated complete reaction. $EtOH$ ethanol was added, the mixture was filtered, and the organic layer was separated and filtered through a short column of silica gel. The column eluted with $EtOAc$ and the eluate was evaporated under reduced pressure. The resulting brown solid (379 mg) contained, according to TLC ($CHCl_3/EtOAc/COH$ 100:10:1), a polar compound as the major component and a less polar impurity. Preparative TLC ($CHCl_3/EtOAc/COH$ 100:10:1) and crystallization from Et_2O /hexane afforded **15a** (122 mg, 27%, mp 247–248 °C dec): $[\alpha]_D -4^\circ$ (c 0.8, dioxane); 1H NMR (in the mixture of $CDCl_3$ and CD_3OD) δ 0.84 (s, 3H, CH_3), 0.86 (s, 3H, CH_3), 0.87 (s, 3H, CH_3), 1.00 (s, 3H, CH_3), 1.09 (s, 3H, CH_3), 2.05 (s, 3H, $OCOCCH_3$), 2.29 (br. m, 2H, $C^{16}H_2$), 2.64 (dd, $J = 11.9$ Hz, $J' = 4.7$ Hz, 1H, $C^{13}HF$), 4.48 (dd, $J = 11.2$ Hz, $J' = 5.1$ Hz, 1H, C^3HF). Ref.²⁵ mp 246–248 °C, hexane/ Me_2CO ; $[\alpha]_D -4.7^\circ$ (c 0.42, $CHCl_3$).

From Acid 3c. A solution of **3c** (200 mg, 0.39 mmol) in $EtOAc$ (5 mL), $MeOAc$ (15 mL), and $MeCN$ (5 mL) was added to a mixture of $Ru(IV)O_2 \cdot H_2O$ (15 mg, 0.11 mmol), $NaIO_4$ (1.8 g, 8.4 mmol), H_2O (15 mL), and CF_3COOH (0.5 mL). The biphasic reaction mixture was stirred vigorously at room temperature for 60 h. Then the reaction mixture was worked up as in the previous example. Diacid **15a** (58 mg 33%, mp 245–247 °C dec): $[\alpha]_D -6^\circ$ (c 0.42, dioxane), was identical to an authentic sample.

From Methylene Ketone 12. A solution of **12** (50 mg; 0.12 mmol) in $EtOAc$ (2 mL) and $MeCN$ (0.5 mL) was added to a mixture of $Ru(IV)O_2 \cdot H_2O$ (1.5 mg, 0.01 mmol), $NaIO_4$ (150 mg, 0.7 mmol), H_2O (2 mL), and CF_3COOH (50 μ L) was stirred vigorously at room temperature for 20 h. The reaction mixture was worked up as in the previous example. The diacid **15a** (22 mg, 39%, mp 244–246 °C dec): $[\alpha]_D -3^\circ$ (c 0.3, dioxane), was identical to an authentic sample.

Dimethyl 3 β -Acetoxy-19,20,21,22,28,29,30-heptanor-17,18-secolupan-17,18-dioate (15b). This compound was obtained by reaction of diacid **15a** with diazomethane (mp 143–145 °C, $MeOH$): $[\alpha]_D +10^\circ$ (c 0.33); 1H NMR δ 0.84 (s, 3H, CH_3), 0.85 (s, 3H, CH_3), 0.87 (d, $J = 0.8$ Hz, 3H, CH_3), 0.99 (s, 3H, CH_3), 1.04 (s, 3H, CH_3), 2.05 (s, 3H, $OCOCCH_3$), 2.62 (dd, $J = 12.7$ Hz, $J' = 4.0$ Hz, 1H, $C^{13}HF$), 3.63 (s, 3H, OCH_3), 3.65 (s, 3H, OCH_3), 4.48 (dd, $J = 11.3$ Hz, $J' = 5.2$ Hz, 1H, C^3HF). Ref.¹⁶ mp 140–144 °C, $EtOH$): $[\alpha]_D +12.2^\circ$ (c 1, $CHCl_3$).

Bis[pivaloyloxy)methyl]3 β -Acetoxy-19,20,21,22,28,29,30-heptanor-17,18-secolupane-17,18-dioate (15c). DBU (17 μ L, 0.11 mmol) and $Pom-Cl$ (16 μ L, 0.11 mmol) were added to a solution of diacid **15a** (25 mg, 57 μ mol) in CH_2Cl_2 (300 μ L) and $MeCN$ (120 μ L). The mixture was stirred at room temperature for 3 h and was then diluted with ice-cold H_2O and extracted with $CHCl_3$. The combined extracts were washed with cold brine. After drying and evaporating, a viscous pale-brown oil (37 mg) was obtained. This was chromatographed on SiO_2 (PhMe/ Et_2O 10:1). Pure **15c** (28 mg, 72%) was obtained as a colorless oil: $[\alpha]_D +19^\circ$ (c 0.46); 1H NMR δ 0.84 (s, 3H, CH_3), 0.85 (s, 3H, CH_3), 0.87 (s, 3H, CH_3), 0.99 (s, 3H, CH_3), 1.06 (s, 3H, CH_3), 1.21 (s, 18H, $C(CH_3)_3$), 2.05 (s, 3H, $OCOCCH_3$), 2.12–2.30 (br m, 2H, $C^{16}H_2$), 2.65 (dd, $J = 12.0$ Hz, $J' = 4.6$ Hz, 1H, $C^{13}HF$), 4.48 (dd, $J = 11.3$ Hz, $J' = 5.0$ Hz, 1H, C^3HF), 5.66 (d, $J = 5.5$ Hz, 1H, OCH_2O), 5.71 (d, $J = 5.5$ Hz, 1H, OCH_2O), 5.74 (d, $J = 5.5$ Hz, 1H, OCH_2O), 5.76 (d, $J = 5.5$ Hz, 1H, OCH_2O); EIMS m/z 678 (M^+ , 0), 647 (6), 604 (2), 587 (63), 503 (13), 489 (16), 444 (18), 419 (11), 375 (19), 359 (13), 331 (7), 315 (21), 276 (21), 249 (9), 229 (16), 203 (8), 189 (100). Anal. ($C_{37}H_{60}O_{10}$) C, H.

Crystallography. Single crystals of β -keto acid **8a** were grown from a $CHCl_3/EtOAc$ /petroleum ether/ $MeOH$ solvent system. Crystal structure data: unit cell parameters, $a = 7.4459(9)$ Å, $\alpha = 90^\circ$, $b = 11.0454(9)$ Å, $\beta = 94.002(11)^\circ$, $c = 36.178(4)$ Å, $\gamma = 90^\circ$; $C_{30.50}H_{50}O_{8.50}$ ($C_{29}H_{44}O_7 \cdot 1.5MeOH$) = 552.70, two unit formulas per unit cell; calculated density 1.237 $Mg\ m^{-3}$; space group $P2_1$; $\lambda = 1.54178$ Å, 10 322 independent reflections collected; the structure was solved by

direct methods and refined by full-matrix least-squares against F^2 (SHELXS-97); the program used for refinement was SHELXL-97; refinement with statistical weights [$w = 1/\sigma^2(F^2)$] gave a final Flack parameter of $-0.05(9)$; the final R value was 3.63%. Full crystallographic data are included in the Supporting Information.

Cell Lines. All cells were purchased from the American Tissue Culture Collection (ATTC), unless otherwise indicated. Cladribine-, gemcitabine-, cytosinarabioside-, and fludarabine-resistant sublines of K562 cells (K562-CdA, K562-GEM, K562-ARA-C, K562-FLUD) were kindly provided by Dr. J. Dummont (University of Lyon, Lyon, France). The drug-resistant sublines of CEM cells (CEM-DNR bulk, CEM-DNR 1/C2, CEM-VCR bulk, CEM-VCR 1/F3, CEM-VCR 3/D5) were selected in our laboratory by the cultivation of maternal cell lines in increasing concentrations of daunorubicine or vincristine, respectively.²⁷ The human T-lymphoblastic leukemia cell line, CEM, was used for routine screening of compounds. To prove a common mechanism of action, selected compounds that showed activity in the screening assay were tested in a panel of cell lines (Table 1). These lines were from different species and of various histogenetic origin, and they possess various alterations in their cell cycle-regulatory proteins and hormone receptor status (Table 1). The cells were maintained in Nunc/Corning 80 cm² plastic tissue culture flasks and cultured in cell culture medium (DMEM/RPMI 1640 with 5 g/L glucose, 2 mM glutamine, 100 U/mL penicillin, 100 μ g/mL streptomycin, 10% fetal calf serum, and NaHCO₃).

Cytotoxic MTT Assay.²⁸ Cell suspensions were prepared and diluted according to the particular cell type and the expected target cell density (2500–30 000 cells/well based on cell growth characteristics). Cells were added by pipet (80 μ L) into 96-well microtiter plates. Inoculates were allowed a preincubation period of 24 h at 37 °C and 5% CO₂ for stabilization. Four-fold dilutions, in 20- μ L aliquots, of the intended test concentration were added at time zero to the microtiter plate wells. All test compound concentrations were examined in duplicate. Incubation of the cells with the test compounds lasted for 72 h at 37 °C, in a 5% CO₂ atmosphere at 100% humidity. At the end of the incubation period, the cells were assayed using MTT. Aliquots (10 μ L) of the MTT stock solution were pipetted into each well and incubated for a further 1–4 h. After this incubation period formazan produced was dissolved by the addition of 100 μ L/well of 10% aqueous SDS (pH = 5.5), followed by a further incubation at 37 °C overnight. The optical density (OD) was measured at 540 nm with a Labsystem iEMS Reader MF. Tumor cell survival (TCS) was calculated using the following equation: $TCS = (OD_{\text{drug-exposed}} / \text{mean } OD_{\text{control}}) \times 100\%$. The TCS₅₀ value, the drug concentration lethal to 50% of the tumor cells, was calculated from appropriate dose–response curves.

Apoptosis and Cell Cycle Analysis by FACS.²⁹ CEM cells (1×10^6 /mL) were cultured in 6-well plates, with or without 10 μ M concentration of BA (**2b**), betulinines, **16**, **4b**, **8a**, and paclitaxel (1 μ M) as a reference drug, at 37 °C and 5% CO₂ for 3–24 h. Following the incubation, cells were pelleted, washed in Hank's buffered salt solution (HBSS), and fixed in 96% ethanol overnight at -20 °C. Low molecular weight apoptotic DNA was extracted in citrate buffer and RNA was cleaved by RNase (50 μ g/mL). The DNA was stained by ethidium bromide, and the cells were analyzed by flow-cytometry using a 488 nm single beam laser (Becton Dickinson, San Jose, CA).

Morphological Analysis of Apoptosis by Scanning Electron Microscopy. CEM cells (1×10^6 /mL) were cultured in 6-well plates, with or without 10 μ M concentration of BA (**2b**), betulinines, **16**, **4b**, and **8a**, at 37 °C and 5% CO₂ for 3–24 h. Following incubation, cells were pelleted, washed in Hank's buffered salt solution, and fixed in 2% glutaraldehyde/HBSS at 4 °C overnight. Cellular suspensions were cytocentrifuged on microscopic slides, dried, and covered with gold under vacuum. The surfaces of (un)treated cells were examined by scanning electron microscope (Tesla BS340) for typical mor-

phological markers of apoptosis: cytoplasmic membrane blabbing, cellular fragmentation, and formation of apoptotic bodies.

Statistics. The cytotoxic activities of BA (**2b**) and the most effective compounds, **16**, **4b**, and **6**, listed in Table 1 were mutually compared in order to investigate for a common mechanism of action. The nonparametric Spearman correlation analysis was performed using software Prisma, version 4.0. The correlation diagrams, correlation coefficients, and statistical significances are shown in Figure 3.

Acknowledgment. This study was supported in part by the Ministry of Education of the Czech Republic (MSM 151100001 and MSM 113100001), the Grant Agency of the Czech Republic (301/03/1570), and the Cancer Research Foundation in Olomouc. We are grateful to Veronika Drabkova, Lenka Surzynova, and Jiri Lipert for excellent technical assistance. The editorial help of Sergej Kuzmin and the electron microscopy services provided by Dr. Radek Novotny are greatly appreciated. We thank also Iva Tislerova for measurement of NMR spectra, Martin Sticha for the mass spectral measurements, and Stanislav Hilgard for measurement of IR spectra. Special thanks to Bohunka Sperlchova for measurement of optical rotations.

Supporting Information Available: Full crystallographic information of β -keto acid **8a** and ¹³C NMR data and expanded cytotoxic activity of all unpublished compounds. This material is available free of charge via Internet at <http://pubs.acs.org>.

References

- Ogura, M.; Cordell, G. A.; Farnsworth, N. R. Potential anticancer agents. IV. Constituents of *Jacaranda caucana* Pittier (*Bignoniaceae*). *Lloydia* **1977**, *40*, 157–168.
- Sheth, K.; Jolad, S.; Wiedhopf, R.; Cole, J. R. Tumor-inhibitory agent from *Hyptis emoryi* (*Labiatae*). *J. Pharm. Sci.* **1972**, *61*, 1819.
- Miles, D. H.; Kokpol, U.; Zalkow, L. H.; Steindel, S. J.; Nabors, J. B. Tumor inhibitors. I. Antitumor activity of *Sarracenia flava*. *J. Pharm. Sci.* **1974**, *63*, 613–615.
- Trumbull, E. R.; Bianchi, E.; Eckert, D. J.; Wiedhopf, R. M.; Cole, J. R. Tumor inhibitory agents from *Vauquelinia corymbosa* (*Rosaceae*). *J. Pharm. Sci.* **1976**, *65*, 1407–1408.
- Sandberg, F.; Duchevska, K.; Khristov, V.; Spasov, S. *Spondianthus preussii* var. *glaber* Engler. Pharmacological screening and occurrence of triterpenes. *Acta Pharm. Suec.* **1987**, *24*, 253–256.
- Ryu, S. Y.; Choi, S. U.; Lee, S. H.; Lee, C. O.; Zaesung, N.; Ahn, J. Antitumor triterpenes from medicinal plants. *Arch. Pharmacol. Res.* **1994**, *17*, 375–377.
- Pisha, E.; Chai, H.; Lee, I.-S.; Chagwedera, T. E.; Farnsworth, N. R.; Cordell, G. A.; Beecher, C. W. W.; Fong, H. H. S.; Kinghorn, A. D.; Brown, D. M.; Wain, M. C.; Wall, M. E.; Hieken, T. J.; Das Gupta, T. K.; Pezzuto, J. M. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. *Nat. Med.* **1995**, *1*(10), 1046–1051.
- Fulda, S.; Friesen, C.; Los, M.; Scaffidi, C.; Mier, W.; Benedict, M.; Nunez, G.; Krammer, P. H.; Peter, M. E.; Debatin, K. M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. *Cancer Res.* **1997**, *57*, 4956–4964.
- Fulda, S.; Scaffidi, C.; Susin, S. A.; Krammer, P. H.; Kroemer, G.; Peter, M. E.; Debatin, K. M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. *J. Biol. Chem.* **1998**, *273*, 33942–33948.
- Mayaux, J.-F.; Bousseau, A.; Pauwels, R.; Huet, T.; Hénin, Y.; Dereu, N.; Evers, M.; Soler, F.; Poujade, C.; De Clercq, E.; Le Pecq, J.-B. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 3564–3568.
- Evers, M.; Poujade, C.; Soler, F.; Ribeill, Y.; James, C.; Lelievre, Y.; Gueguen, J. C.; Reisdorf, D.; Morize, I.; Pauwels, R.; De Clercq, E.; Hénin, Y.; Bousseau, A.; Mayaux, J.-F.; Le Pecq, J.-B.; Dereu, N. Betulinic acid derivatives: A new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. *J. Med. Chem.* **1996**, *39*, 1056–1068.
- Kim, D. S. H. L.; Pezzuto, J. M.; Pisha, E. Synthesis of betulinic acid derivatives with activity against human melanoma. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1707–1712.

- (13) Setti, E. L.; Mascaretti, O. A. Synthesis of (pivaloyloxy)methyl 6-fluoropenicillanate. *J. Chem. Soc., Perkin Trans. 1* **1988**, 2059–2060.
- (14) Suokas, E.; Hase, T. Triterpenes. A novel acid-catalyzed double bond migration in 3 β ,28-diacetoxy-lup-20(30)-ene (betulin diacetate). *Acta Chem. Scand., Ser. B* **1975**, 29, 139–140.
- (15) Sejbal, J.; Klinot, J.; Budesinsky, M.; Protiva, J. Functionalization of 3 β ,28-lupanediol diacetate with chromium(VI) oxide. *Collect. Czech. Chem. Commun.* **1991**, 56, 2936–2949.
- (16) Klinotova, E.; Cermakova, J.; Rejzek, M.; Krecek, V.; Sejbal, J.; Olšovsk, P.; Klinot, J. Reaction of 18 β ,19 β -epoxylupan-21-one derivatives with acids: A way to 21,22-disubstituted lup-18-ene triterpenoids. *Collect. Czech. Chem. Commun.* **1999**, 64, 329–347.
- (17) Baddeley, G. V.; Simes, J. J. H.; Watson, T. G. The oxidation of methyl acetylbutulate and methyl acetylmelaleucate by mercuric acetate. *Aust. J. Chem.* **1971**, 24, 2639–2648.
- (18) Denisenko, M. V.; Odinkova, L. E.; Denisenko, V. A.; Uvarova, N. I. Retro aldol reaction of 28-hydroxy-18,19-secolupane-18,19-dione derivatives or oxidation of 28-hydroxy-18-lupane derivatives with ruthenium tetroxide—Synthetic route to 28-nor-18,19-secolupane-18,19-dione derivatives. *Zh. Org. Khim.* **1991**, 27, 2174–2181.
- (19) Klinotova, E.; Rejzek, M.; Zunova, H.; Sejbal, J.; Klinot, J.; Urgan, J. Oxidation of 3 β ,28-diacetoxy-18-lupen-21-one with peroxy acids: A way to des-E-lupane derivatives. *Collect. Czech. Chem. Commun.* **1993**, 58, 2505–2516.
- (20) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. A greatly improved procedure for ruthenium tetroxide catalyzed oxidations of organic compounds. *J. Org. Chem.* **1981**, 46, 3936–3938.
- (21) Sarek, J.; Klinot, J.; Klinotova, E.; Sejbal, J. Double-bond cleavage in 18-lupane derivatives by ruthenium(VIII) oxide—Path to des-E-lupane compounds. *Chem. Listy* **1997**, 11, 1005–1006.
- (22) Suokas, E.; Hase, T. Triterpenes. *p*-Toluenesulfonic acid catalyzed rearrangement of 18 α ,19 α and 18 β ,19 β isomers of 3 β ,28-diacetoxy-epoxylupane. *Acta Chem. Scand., Ser. B* **1977**, B31, 182–184.
- (23) Hajduch, M.; Sarek, J. Triterpenoid derivatives. PCT Intl. Patent Appl. Publ. WO 2001090136.
- (24) Odinkova, L. E.; Denisenko, M. V.; Denisenko, V. A.; Uvarova, N. I. Retro-Michael reaction of 28-methoxy-18,19-secolupane-18,19-dione derivatives. *Khim. Prir. Soedin.* **1992**, 210–215.
- (25) Denisenko, M. V.; Pokhilo, N. D.; Odinkova, L. E.; Denisenko, V. A.; Uvarova, N. L. Ruthenium tetroxide oxidation of 3 β -acetoxy-28-hydroxy-18-lupene to tricyclic products. *Tetrahedron Lett.* **1996**, 37, 5187–5190.
- (26) Dinda, B.; Hajra, A. K.; Das, S. K.; Chel, G.; Chakraborty, R.; Ranu, B. C. Reactions on naturally occurring triterpene: Part I. *Ind. J. Chem.* **1995**, 34B, 624–628.
- (27) Nosková, V.; Džubák, P.; Kuzmina, G.; Ludková, A.; Stehlík, D.; Trojanec, R.; Janostakova, A.; Korinkova, G.; Mihal, V.; Hajduch, M. In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF-CEM, K562, A549 and MDA MB 231 parental cells. *Neoplasma* **2002**, 49, 416–423.
- (28) Hajduch, M.; Mihal, V.; Minarik, J.; Faber, E.; Safarova, M.; Weigl, E.; Antalek, P. Decreased in vitro chemosensitivity of tumour cells in patients suffering from malignant diseases with poor prognosis. *Cytotechnology* **1996**, 19, 243–245.
- (29) Shankey, T. V.; Rabinovitch, P. S.; Bagwell, B.; Bauer, K. D.; Duque, R. E.; Hedley, D. W.; Mayall, B. H.; Wheelless, L.; Cox, C. Guidelines for implementation of clinical DNA cytometry, International Society for Analytical Cytology. *Cytometry* **1993**, 14, 472–477.

JM020854P